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Owing in large part to the low regenerative capacity of the heart, cardiovascular disease 
(CVD) remains a leading cause of morbidity and mortality worldwide.  Compelling evidence 
suggests the presence of resident cardiac precursor cells (CPCs) in the neonatal and, to a lesser 
extent, in the adult myocardium.  These CPCs are identified based on specific marker expression 
including c-kit, a type III receptor tyrosine kinase.  
Here we report the isolation and characterization of neonatal c-kit
+
 CPCs from a bacterial 
artificial chromosome (BAC) transgenic mouse in which enhanced green fluorescent protein 
(EGFP) is driven by the kit locus.  We demonstrate that c-kit expression identifies CPCs capable 
of expanding and differentiating into all three cardiac lineages.  In addition, we establish that this 
mesodermally derived cell population comprises a mixture of precursors and more mature cells 
in the early stages of lineage commitment. 
Progressing from the identification of CPCs, cell-based therapy has emerged as a strategy 
for cardiac repair.  However, the pathological environment of the infarcted heart, attributed in 
part to the production of reactive oxygen species (ROS), impedes transplanted cell survival.  In 
spite of well-known pathological roles, ROS also participate in normal cell development and 
recent research indicates that redox state is a critical regulator of precursor cell function. 
Because the NADPH oxidases (Nox) are a major source of ROS in the heart, a significant 
amount of research has been conducted to elucidate roles for these enzymes in cardiomyogenesis 
and heart failure.  However, little research has been directed at the function of Nox enzymes in 
 CPCs.  As a successful cell-based therapy requires both the survival of transplanted cells and 
their differentiation into cardiomyocytes, understanding the mechanisms of ROS signaling in 
CPCs is critical.   
Therefore, utilizing genetic tools to manipulate the Nox enzymes of neonatal c-kit
+
 CPCs, 
I demonstrate that specific cardiac Nox homologues are critical modulators of c-kit
+
 cell 
precursor and differentiation status.  I speculate that these and other redox genes identified by 
messenger RNA (mRNA) arrays will provide novel targets for improving the regenerative 
capacity of c-kit
+
 CPCs, which can later be integrated into cell-based therapies for myocardial 
infarction (MI). 
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CHAPTER ONE: INTRODUCTION  
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1.1 Cardiovascular Disease (CVD) 
 
1.1.1 Prevalence in the United States 
The term cardiovascular disease (CVD) encompasses a large group of cardiac afflictions 
including, but not limited to, coronary heart disease (CHD), stroke, high blood pressure, 
congenital defects, and heart failure.  Risk factors for non-congenital CVD include high total 
cholesterol, hypertension, cigarette use, physical inactivity, obesity, and diabetes.  According to 
the most recent Heart Disease and Stroke Statistics released by the American Heart Association 
1
, CVD was responsible for approximately one-third of all deaths in the United States in the year 
2006.  This accounted for more deaths than cancer, chronic lower respiratory disease, and 
accidents, combined.  Interestingly, over half of these deaths were attributed to CHD, a category 
which comprises both chest pain and myocardial infarction (MI), more commonly known as a 
heart attack.  In addition to these jarring statistics, the report predicted that close to 800,000 
Americans would experience a new coronary event in the year 2010, causing roughly one death 
every minute.   
 
Unfortunately, within the first five years after a MI, approximately 33% of men and 43% of 
women ≥40 years of age will die and many others will be diagnosed with heart failure 1.  
Because heart transplantation continues to provide the only cure for heart disease, doctors 
perform procedures aimed to ameliorate symptoms such as percutaneous coronary intervention 
(PCI), bypass surgeries, and defibrillator/pacemaker implantations with the hope that they can 
improve the quality of life for their patients.  It is this lack of a true cure for heart disease along 
with extensive treatment and inpatient/outpatient care that lead to combined costs associated with 
CHD staggering at well over $150 billion per year.  Due to the severe shortage of hearts 
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available for organ donation and subsequent transplantation, basic research in the CHD field has 
turned its focus to cell populations which retain lineage plasticity and the potential for cardiac 
commitment.  Discovering these cell types and determining their usefulness in cardiac 
regeneration have been topics of great interest over the last decade and serve as the foundation 
for this dissertation.  However, it took years of research to disprove paradigms regarding the 
proliferative capacity of the mature heart that were established close to 100 years ago. 
1.1.2 Paradigm Shift from a Terminally Differentiated Heart to a Self-Renewing Organ  
Dating back to the mid-1800’s and the early-1900’s, the adult human heart was viewed as an 
organ capable of expansion through both hyperplasia (increase in the number of cells) and 
hypertrophy (increase in the size of cells) of existing myocytes.  In the early- to mid-1900’s, 
however, this dogma was challenged by several groups including Karsner who, in 1925, claimed 
that the heart grew in size via hypertrophy alone and that there was no direct evidence (i.e. signs 
of mitotic myocytes) supporting the ability of the heart to experience hyperplasia of existing 
fibers 
2
.  By the mid-1900’s, a majority of researchers in the field refuted the idea of myocyte 
proliferation 
3
 with only a minority, specifically Linzbach in the late 1940’s, propagating a 
theory of myocyte proliferation limited to the pathologically hypertrophied heart 
4
.  Although 
faced with some opposition, it was generally accepted throughout the remainder of the 20th 
century that the heart was a terminally differentiated organ and it is this paradigm that shaped 
basic and clinical research for several decades to come.    
 
In 1998, however, Kajstura, et al. 
5
 utilized confocal microscopy to conclusively demonstrate a 
very low but detectable mitotic index in non-diseased human hearts of 14 myocytes per million 
with a ten-fold increase in mitotic index found in samples from patients with heart failure.  That 
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same year, together with Anversa, Kajstura published a review further supporting the notion that 
ventricular myocytes are not terminally differentiated and advancing the concept that myocyte 
proliferation can be enhanced by stimulation with growth factors such as insulin-like growth 
factor (IGF)-1 
6
.  In 2001, Beltrami, et al. 
7
 provided additional evidence challenging the dogma 
that the heart was a post-mitotic organ by demonstrating the presence of Ki-67 (marker of 
proliferation) staining in approximately 4% of myocytes in the border zone of infarcted human 
hearts.  Whether or not these proliferating cells represented a sub-population of myocytes 
capable of division, a population of extra-cardiac stem cells, or an endogenous precursor cell 
population, however, remained largely unknown. 
 
In the early years of the 21
st
 century, cardiac chimerism in the transplanted heart offered skeptics 
even more evidence of cardiac self-renewal, utilizing the presence of the Y-chromosome to 
distinguish between graft and host tissue 
8, 9
.  However, it was not until 2009, years after the 
discovery of endogenous cardiac precursor cells (CPCs) which will be discussed in detail in later 
sections, that Bergmann, et al. 
10
 generated the most conclusive evidence to date demonstrating 
cardiomyocyte renewal in humans.  In this elegant series of experiments, the group utilized 
knowledge of the integration of carbon-14 into DNA released atmospherically during nuclear 
bomb testing of the Cold War to date human cardiomyocytes 
10
.  They reported that 
cardiomyocytes in the human heart are renewed at a rate of 1% per year at 25 years of age with a 
close to 50% reduction in renewal rate by the age of 75.  While these studies established 
conclusively the ability of cardiomyocytes to undergo cell proliferation, they also highlighted the 
fact that, at these rates, only 50% of myocytes are replaced during the lifetime, a speed at which 
substantial cardiac regeneration after injury such as MI is improbable.  Most recently, it was 
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demonstrated that hearts from early postnatal (PN) mice (PN1) can regenerate after surgical 
resection of the left ventricular apex 
11
.  In this study, the regenerative process was marked by 
cardiomyocyte proliferation with little hypertrophy or fibrosis which are two hallmarks of the 
adult repair response.  Interestingly, the investigators reported that this capacity to restore 
resected myocardium diminishes completely by PN7.  The mechanisms by which this 
competence declines during the first week post-birth remain to be elucidated and likely will 
uncover novel therapeutic targets for cardiac repair.  
1.1.3 Myocardial Infarction (MI) 
MI is an acute form of CHD which affects over 8 million Americans each year 
1
.  MI typically 
begins when a coronary artery becomes occluded by a dislodged atherosclerotic plaque.  This 
disruption in blood flow to the heart triggers a period of ischemia marked by hypoxia and 
hypoglycemia which results in damage to cell membranes and massive cell death by necrosis.  
Following a prolonged period of ischemia and subsequent induction of reperfusion, the heart 
experiences a further increase in the production of reactive oxygen species (ROS), which are 
extremely unstable and highly reactive molecules such as superoxide and hydrogen peroxide 
(H2O2), from several sources (i.e. mitochondria, xanthine oxidases, nicotinamide adenine 
dinucleotide phosphate [NADPH] oxidases) along with a surge in inflammatory cytokines 
12
.  
Together, the production of free radicals and activation of complement drive a cytokine cascade 
mediated by tumor necrosis factor (TNF)- α, interleukin (IL)-1β, and IL-6 that signals the 
recruitment of neutrophils to the damaged area 
13
.  Ultimately, the cytokine cascade ends by 
triggering apoptosis in a large portion of the damaged cells giving way to matrix 
metalloproteinases (MMPs) which degrade extracellular matrices and mark the beginning of left 
ventricular (LV) remodeling. 
 6 
 
Although thought to be the heart’s attempt at healing, LV remodeling actually causes irreversible 
harm to the organ and drastically reduces its pumping capacity.  This damaging remodeling is 
marked by processes such as hypertrophy of non-damaged regions, dilatation, thinning of the 
myocardial wall, and stiffness due to excessive collagen deposition and fibrosis 
14
.  Although it is 
now understood that a sub-population of cells in the heart are capable of proliferation, the 
regenerative potential of these cells is grossly inadequate to compensate for the immense loss of 
cardiomyocytes that occurs following MI.  Therefore, LV remodeling in conjunction with 
insufficient cardiac regeneration increase a patient’s risk for future arrhythmias, leading to 
progressively worse heart disease and ultimately to heart failure.   
1.1.4 Summary 
With such a high prevalence of CHD in the United States together with the heart’s inability to 
regenerate itself after injury despite the presence of proliferative-competent cells, there has been 
a shift in the focus of cardiovascular research in recent years.  While some research in the field 
focuses on finding ways to stimulate existing populations of proliferating cells in the adult heart 
to participate in cardiac regeneration, a majority of research in the field has turned to a cell-based 
therapy approach whereby cells with cardiac potential are injected into the infarcted heart with 
the hope that they will survive, proliferate, and differentiate into fully functional cardiomyocytes.  
 
1.2 Cardiac Cell-Based Therapy 
  
1.2.1 Extra-Cardiac Stem Cell Sources 
Cell-based therapy is currently at the forefront of cardiovascular basic and clinical research, 
providing promise for a treatment that can improve the function and overall health of the heart 
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without necessitating a heart transplantation.  Some of the earliest attempts at cell-based therapy 
utilized skeletal myoblasts, cells that normally regenerate skeletal muscle, in cardiac 
regeneration.  While these early studies reported functional improvement following 
transplantation 
15
, later studies failed to demonstrate differentiation of these cells to 
cardiomyocytes or their electrical coupling through gap junctions with the rest of the heart 
16-19
.  
Clinical trials from skeletal myoblast engraftments revealed an increased risk for arrhythmia and, 
consequently, resulted in internal defibrillator implantation in several patients under study 
20
.  In 
addition to skeletal myoblasts, many other stem cell types including bone marrow (BM)-derived 
cells, embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs) have been 
investigated for their therapeutic potential in myocardial regeneration.  Each is discussed below 
in turn. 
1.2.1.1 Bone Marrow (BM)-Derived Cells 
Around the same time that skeletal myoblasts were being assessed for a role in cardiac 
regeneration, Orlic, et al. 
21
 reported that BM-derived hematopoietic stem cells (HSCs) 
with a Lin
-
c-kit
+
 phenotype were capable of initiating de novo myocardial regeneration in 
the infarcted murine heart.  This initial finding, however, was met with opposition several 
years later when two independent laboratories reported that HSCs were unable to acquire 
a cardiac phenotype and that previous reports were likely a product of cellular fusion, not 
transdifferentiation 
22, 23
.  In a rebuttal to these findings, Anversa’s group published yet 
another report reaffirming that BM-derived cells were capable of cardiac differentiation 
independent of cell fusion 
24
.  While this controversy is ongoing, beneficial effects after 
transplantation of BM-derived cells such as endothelial progenitor cells (EPCs) 
25
, 
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mesenchymal stem cells (MSCs) 
26
, and c-kit
+ 
cells 
27
 whether the result of true cardiac 
differentiation or strictly paracrine effects, have since been reported.    
1.2.1.2 Embryonic Stem Cells (ESCs) 
In recent years, ESCs derived from the inner cell mass of the early blastocyst have been 
the topic of much debate.  In 2001, it was first reported that human ESCs can differentiate 
into fully functioning myocytes in vitro 
28
.  These myocytes express typical markers of 
cardiac differentiation including Gata4, Nkx2.5, atrial natriuretic peptide (ANP), and 
cardiac Troponin T (cTnT).  This finding sparked great interest in the potential of ESC-
derived cardiomyocytes for myocardial repair.  The following year, Xu, et al. 
29
 built 
upon this work by developing an enrichment strategy to isolate human ESC-derived 
cardiomyocytes by Percoll density gradient to a purity of approximately 70%.  Protocols 
for cardiac enrichment have since improved, and both murine and human ESC-derived 
cardiomyocytes have been used to create myocardial grafts in rodents in the presence and 
absence of MI 
30-33
.  Together, these studies demonstrate long-term engraftment potential 
and enhanced LV cardiac function with no signs of graft rejection or tumor formation.  
However, despite these promising results, the use of ESCs remains highly controversial 
due to ethical concerns and the risk for teratoma formation in both allogeneic and 
syngeneic hosts.   
1.2.1.3 Induced Pluripotent Stem Cells (iPSCs) 
Most recently, iPSCs have risen to the forefront of cell-based therapy research, as their 
discovery circumvents the ethical concerns associated with ESCs.  iPSCs first were 
generated from mouse skin fibroblasts utilizing the exogenous expression of four genes, 
Oct2/4, Sox2, Klf4, and c-myc 
34
.  Soon after, similar reprogramming was achieved in 
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human dermal fibroblasts 
35, 36
.  As with ESCs, several groups demonstrated the ability of 
iPSCs to differentiate into fully functioning cardiac myocytes in vitro 
37-39
.  However, 
when transplanted directly into the infarcted heart, undifferentiated iPSCs were found to 
induce teratoma formation 
40, 41
.  While reprogramming cardiac fibroblasts into 
cardiomyocyte-like cells using transcription factors Tbx5, Gata4, and Mef2c may 
circumvent some of these problems associated with pluripotency 
42
, further investigation 
into the safety and therapeutic potential of these stem cells is necessary before being 
considered a candidate population for clinical trials.  
1.2.2 Identification of Cardiac Precursor Cells (CPCs) 
In 2002, it was first documented that the PN heart, like other organs, contains side population 
(SP) cells which are capable of excluding Hoechst dye, display stem cell-like behavior, and lack 
markers of differentiation 
43
.  When isolated from mature mice, these cells represented 
approximately 1% of the total heart cells, but were negative for additional stem cell markers such 
as c-kit and Sca-1 which mark SP cells isolated from other organ systems.  One year later, 
pioneering research from Anversa’s laboratory in the newly established CPC field demonstrated 
that Lin
-
c-kit
+
 cells isolated from the adult rat heart are self-renewing, clonogenic, and 
multipotent and can be differentiated into smooth muscle, endothelial, and cardiac cells 
44
.  This 
work was supported three years later by data from Orkin’s group which indicated that c-kit is a 
CPC marker that identifies a subpopulation of Nkx2.5
+
 cells with lineage bipotential 
45
.  In this 
study, c-kit
+
Nkx2.5
+
 mouse ESCs were isolated and shown to be bipotent in that they could 
differentiate into smooth muscle and cardiac cells when plated as single cells in vitro as well as 
through chick xenograft assays in vivo.  As will be presented in Chapter 2, work from our 
laboratory in 2009 further indicates that c-kit characterizes a cardiovascular precursor cell 
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population within the PN heart that can be expanded and differentiated in vitro into all three cell 
lineages that specify the heart 
46
.  The therapeutic potential of these cells in treating myocardial 
infarction in rodents also has been evaluated with moderate success 
44, 47, 48
. 
 
Current evidence suggests that additional CPC populations exist and can be identified based on 
the expression of various cell markers including Abcg2, stem cell antigen (Sca)-1, fetal liver 
kinase (Flk)-1, and islet (Isl)-1.  To date, it is still unknown whether or not these populations 
represent a single stem cell population at various stages of development or completely distinct 
cell populations.  The origin of these precursor cells also is under scrutinizing debate.  
Interestingly, in the canine heart it has been reported that overlap in expression of several stem 
cell antigens is common, with a majority of cardiac stem cells co-expressing MDR1 (similar to 
Abcg2), Sca-1, and c-kit 
49
.  Below, each of the various cardiac stem cell markers is discussed in 
turn. 
1.2.2.1 Abcg2/MDR1 
In 2003, the same year that c-kit
+
 precursor cells were found to have multilineage 
potential, Martin, et al. 
50
 found that the adult mouse heart also contains SP progenitor 
cells expressing the ATP binding cassette transporter, Abcg2, which effluxes Hoechst 
dye.  Unlike Hierlihy’s purported SP population 43, these SP cells co-expressed Sca-1 as 
well as low levels of c-kit, CD34 (endothelial precursor marker), and CD45 
(hematopoietic precursor marker).  In this study, SP cells isolated from the adult heart 
were shown to proliferate and differentiate along mesodermal lines.  In a more recent 
study, it was observed that cell outgrowths from cardiac biopsies in the rat contain a 
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small population of progenitor cells marked by both Abcg2 and c-kit which, when 
introduced into the infarcted heart, initiate repair and induce functional benefits 
51
.   
1.2.2.2 Sca-1 
Along with the identification of c-kit as a potential marker of adult CPCs by Anversa’s 
laboratory, Oh, et al. 
52
 isolated cardiogenic Sca-1
+
 cells from the mouse myocardium and 
found that they home to the infarcted myocardium after intravenous injection and 
differentiate into myocytes via both fusion and non-fusion events.  A year later, 
Matsuura, et al. 
53
 also identified that Sca-1 marks a population of adult mouse cardiac 
cells capable of differentiating into beating cardiomyocytes in vitro when treated with 
oxytocin.  The Sca-1
+
 precursor cell population has since been used therapeutically in 
mice following MI with some success 
54, 55
.  Most recently, Nkx.2.5
+
Sca-1
+
 embryonic 
epicardial progenitor cells were shown to play a key role in de novo cardiomyocyte 
generation within the thymosin β4 primed heart after infarct, providing clues into the 
mechanisms by which resident CPCs can be mobilized post-ischemic injury 
56
.  However, 
the human homologue for Sca-1 has yet to be uncovered, severely limiting the therapeutic 
potential of this population 
57
 . 
1.2.2.3 Flk-1 
In 2006, Kattman, et al. 
58
 demonstrated that a Flk-1
+
 population derived from embryoid 
bodies (EBs) displays multilineage potential and that these multipotent cells also can be 
isolated from the head-fold-stage embryo.  Several years later, Yang, et al. 
59
 established 
that human cardiovascular progenitor cells are derived from Flk-1
+
 ESCs.  More recently, 
Fatma, et al. 
60
 reported that activation of endogenous c-kit
+
Flk-1
+
 cells in the infarcted 
heart enhances neovascularization and leads to improved cardiac function. 
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1.2.2.4 Isl-1 
The LIM homeobox transcription factor, Isl-1, also has been identified as a marker of 
cells in the PN heart capable of differentiating into functionally mature cardiomyocytes 
61
.  Interestingly, this population is limited in expression to the secondary heart field, 
contributing mainly to the right ventricle, atria, and outflow tract of the mature heart.  In 
2006, Moretti, et al. 
62
 expanded the view of Isl-1 cells by demonstrating that Isl-1
+
 ESCs 
which later co-express Flk-1 and Nkx2.5 are capable of differentiating into smooth 
muscle, endothelial, and cardiac cells.  Unfortunately, it also was reported that the 
presence of these cells rapidly declines after birth, severely limiting the population’s 
therapeutic potential.  In recent years, however, it has been shown that Isl-1
+
 cells can be 
generated from iPSCs and differentiated into all three cardiac lineages in vivo without the 
formation tumors 
39
.  Even so, the stemness of this population has been called into 
question as its expression is linked to pre-commitment to the myocyte lineage 
63
 and the 
population lacks clonogenicity, but produces small colonies in vitro 
64
.  Therefore, the 
clinical applicability of Isl-1
+
 cells in cardiac repair remains to be seen. 
1.2.3 Summary 
Taken together, these data identify populations of stem cells capable of cardiac regeneration and 
confirm the presence of resident CPC populations in the PN and adult myocardium that maintain 
an innate ability to generate all three lineages that specify the heart.  Although numerous 
attempts at cell-based therapy have proven promising in some regards, the field has yet to 
identify the ideal cell type, cell number, and cell delivery method necessary for significant 
cardiac regeneration.  In addition, reasons as to why resident precursor cells do not play a more 
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significant role in cardiac regeneration upon damage to the adult myocardium remain to be 
elucidated. 
 
1.3 Redox Status of Stem Cells 
 
1.3.1 Enhanced Stress Defense Mechanisms 
Around the same time that resident CPCs were discovered in the adult myocardium, the 
mechanisms regulating stem cell self-renewal and differentiation were beginning to be 
elucidated.  With a shared interest in regenerative biology and the recent detection of resident 
progenitor populations in several organ systems, stem cell biologists hypothesized that various 
stem cell populations might share fundamental properties and regulatory pathways.  Utilizing 
gene expression arrays, a stem cell molecular signature was reported in 2002 by comparing the 
transcriptional profiles of HSCs, neural stem cells (NSCs), and ESCs 
65
.  Interestingly, 283 of the 
4289 genes under study were shared among all three groups.  A similar analysis that same year 
revealed 230 shared genes, painting a picture of stem cells as a population highly resistant to 
stress with upregulated detoxifier and DNA repair systems 
66
.  In 2004, this phenomenon was 
extended to EPCs, when it was reported that EPCs isolated from the peripheral blood exhibit 
increased expression of several antioxidants including catalase, glutathione peroxidase, and 
manganese superoxide dismutase (SOD).  The authors speculated that this redox profile was 
necessary for progenitor cells to survive and contribute to neovascularization following ischemic 
injury 
67
.  Most recently, it was observed that iPSCs reclaim an enhanced defense system in 
conjunction with decreased production of ROS mediated, in part, by reduced mitochondrial 
biogenesis 
68
.   
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Interestingly, the protected redox state of stem cells described above was found to decline upon 
differentiation and lineage commitment.  In the early 2000’s, several reports confirmed that stem 
cell differentiation is accompanied by the downregulation of antioxidant and detoxifier genes as 
well as an increase in mitochondrial biosynthesis 
69-71
.  In addition, a recent report identified 
increased generation of mitochondrial ROS as a critical modulator in the formation of ESC-
derived cardiomyocytes, without which cardiac differentiation is drastically reduced 
72
.  
Together, these studies support the idea that a low ROS environment is a pre-requisite for 
multipotency and advance the theory that a redox-dependent molecular switch is necessary for 
stem cell differentiation.   
1.3.2 Redox Regulation of Stem Cell Behavior 
Further investigation into the redox state of precursor cells revealed that slight changes in redox 
balance greatly affect cell function, making cells more or less susceptible to signal transduction 
pathways regulating survival, proliferation, and differentiation.  These studies proposed that 
redox mechanisms are critical for both stemness and differentiation with a more reduced 
environment conducive to cell survival and cell division and a more oxidized condition favoring 
differentiation and/or apoptosis 
73-77
.  Interestingly, in spite of their well-known pathological 
roles, at low levels, ROS (i.e. superoxide, H2O2) are involved in many physiological signaling 
pathways including those necessary for normal cell development and tissue-injury response.  In 
the late 1990’s, it was reported that H2O2, a main and highly diffusible form of ROS, is involved 
in the differentiation of osteoclast precursor cells into bone 
78
.  Shortly thereafter, a slightly more 
oxidized environment generated exogenously by application of a pharmacological pro-oxidant 
was found to drive the differentiation of oligodendrocyte precursor cells, while a more reduced 
environment seemed necessary for cell maintenance and self-renewal 
79
.  This theory soon was 
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extended to the BM lineages when low levels of ROS were found to be critical for the self-
renewal capacity of HSCs 
80
 as well as HSC-derived CD34
+
 cord blood progenitors 
81
, while 
increased ROS was shown to play a crucial role in their differentiation 
82
.  Although the 
mechanisms of action regulating these processes are still under investigation, it is thought that 
redox sensitive transcription factors, kinases, phosphatases, enzymes, and ion channels are all 
involved. 
1.3.3 Summary 
Taken together, these studies suggest that the redox state of a precursor cell is critical for its 
function, making ROS important targets in cardiac cell-based therapy as they mediate the 
signaling pathways necessary for successful engraftments.  Over the past few years, a significant 
amount of research has been conducted to tease apart the function of ROS generators, 
specifically NADPH oxidases (Nox), in the heart and to determine their roles in developmental 
cardiomyogenesis.  Elucidating these pathways and translating the mechanisms required for 
normal heart development to resident CPC function likely will advance treatments for heart 
disease. 
 
1.4 Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidases (Nox) 
 
1.4.1 Main Reactive Oxygen Species (ROS) Generators in Cardiac Cells 
Nox enzymes are the main ROS generators in cardiac cells, critically involved in cell signaling 
and cardiac function 
83-85
.  The Nox family is composed of seven members, Nox1-5 and dual 
oxidases (Duox) 1-2.  These enzymes generate superoxide in a highly regulated manner by 
catalyzing the one electron reduction of molecular oxygen using NADPH as an electron donor.  
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Each of the seven Nox isoforms is encoded by its own gene and shares structural similarity to the 
other isoforms including a cytoplasmic N-terminus, six transmembrane spanning domains, two 
heme binding sites at helices 3 and 5, and a C-terminal tail containing the flavin adenine 
dinucleotide (FAD) and NADPH binding sites (Figure 1.1) 
86-88
.  In addition to these shared 
structural characteristics, Nox5 contains a calmodulin-like domain with four calcium binding 
sites and the more structurally complex Duoxes demonstrate both calcium binding and a 
peroxidase-like domain at the N-terminus.  Interestingly, only Nox1, 2, and 4 are expressed in 
the cardiovascular system and, therefore, will be the focus of this discussion.  The other Nox 
isoforms have various tissue distributions with Nox3 expressed in the inner ear, Nox5 expressed 
in humans, but not in rodents, and the Duoxes limited in their expression to the thyroid tissue 
89
.  
Unlike the neutrophil oxidases which release a large “respiratory burst” of superoxide to ward 
off pathogens 
90
, the cardiovascular Noxes generate lower levels of intracellular ROS which act 
as second messengers that are necessary for cell signaling.  These cardiac Nox enzymes exhibit 
cell-type specific expression patterns and vary in their needs for regulatory subunits.  Each of the 
respective cardiovascular Noxes is discussed below in detail. 
1.4.1.1 Nox2 
Nox2 is the prototypical Nox isoform, originally named gp91
phox
 for its role as a 
phagocytic oxidase in host defense and innate immunity 
89
.  Following its initial 
discovery in macrophages and neutrophils, Nox2 was found to be expressed in several 
cell types including those of the cardiovascular system; endothelial cells, cardiomyocytes, 
fibroblasts, and vascular smooth muscle cells (VSMCs) 
85
.  In the cell, Nox2 is 
predominantly localized to the plasma membrane, caveolae, and endosomes, but it also  
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Figure 1.1.  Structures of the Nox Enzymes 
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has been found in the nucleus of apoptotic cardiomyocytes where it likely plays an 
important role in programmed cell death 
91, 92
.  The activity of Nox2 is well regulated and 
dependent on the presence of five additional subunits; p22
phox
, p47
phox
, p67
phox
, p40
phox
, 
and Rac1/2.  At rest, Nox2 and p22
phox
 exist as a membrane bound dimer known as 
cytochrome b558, while p47
phox
, p67
phox
, and p40
phox
 are maintained as a ternary complex 
in the cytosol with Rac1/2 bound nearby to its inhibitory protein Rho-GDP dissociation 
inhibitor (GDI).  Upon stimulation by various agonists which will be discussed in detail 
in the following sections, p47
phox
 is phosphorylated by protein kinase (PK) C at several 
serine sites initiating a conformational change and the subsequent release of an auto-
inhibitory binding domain.   This activated form of p47
phox
 next transports tethered 
p67
phox
 and p40
phox
 to the membrane where the three subunits attach to membrane bound 
cytochrome b558.  In the final stages of assembly, p67
phox
 binds Rac1/2 after guanine 
nucleotide exchange, completing the third trigger event necessary for Nox2 activity 
87
. 
1.4.1.2 Nox1 
During the 1990’s, researchers discovered ROS production in several cell types other 
than phagocytes that seemed to be generated by a flavoprotein and not as a byproduct of 
cellular respiration.  This finding led to the discovery of the first of the Nox homologues 
in 1999 
86
.  Nox1, which was initially cloned from colon epithelial cells, has since been 
found to be expressed in VSMCs of the cardiovascular system 
85
 where it was recently 
shown to play a critical role in cell migration, proliferation, and matrix production 
93
.  
Similar to Nox2, this Nox isoform is localized in cells to the plasma membrane, caveolae, 
and endosomes 
92
.  However, unlike Nox2, the Nox1 system has relatively few trigger 
events necessary for its activation.  While Nox1 requires p22
phox
 and homologues of 
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p47
phox
 (NoxO1) and p67
phox 
(NoxA1) for its activity, this isoform is already associated 
with p22
phox
, NoxO1, and NoxA1 at the plasma membrane under basal conditions.  
Therefore, the only trigger event necessary for ROS production by Nox1 is guanine 
nucleotide exchange on Rac1/2 
87
.   
1.4.1.3 Nox4 
Of the cardiac Nox isoforms, Nox4 is more distantly related to Nox2 and Nox1 
87
.  This 
Nox enzyme is expressed at high levels in the kidney, but it is also found in all four 
cardiovascular cell types; endothelial cells, cardiomyocytes, fibroblasts, and VSMCs 
85, 
94
.  Unlike Nox2 and Nox1 which are mainly localized to the plasma membrane, Nox4 is 
found in focal adhesions, the nucleus, endoplasmic reticulum, and mitochondria 
92, 95, 96
.  
In cardiomyocytes, Nox4 is mainly localized to the mitochondria 
96
.  While Nox4 exists 
at the membrane in a heterodimer with p22
phox
, it does not require p47
phox
, p67
phox
, 
p40
phox
, or Rac1/2 for its activity.  Therefore, some believe Nox4 to be a constitutively 
active Nox isoform 
89
.  However, because Nox4 is induced by the hormone insulin in a 
manner too fast to be explained solely by protein synthesis, unknown mechanisms likely 
exist to regulate its activity 
87, 97
.  Along these lines, purported binding partners of Nox4 
have been identified recently including Poldip2 
98
.  In addition, some research indicates 
that Nox4 produces H2O2 directly instead of superoxide, adding even more complexity to 
the mechanistic actions of this Nox isoform 
99
. 
1.4.2 Regulation of Activity and Potential Downstream Targets 
The activity of the cardiovascular Nox enzymes in the cell is very well controlled, allowing for 
the production of ROS in a highly regulated manner as opposed to superoxide generation as a 
mere byproduct of other reactions.  Thus far, several agonists for Nox 1, 2, and 4 have been 
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identified including G-protein coupled receptor agonists such as angiotensin-II, endothelin-1, and 
α-adrenergic agonists 85.  In addition to these agonists, Nox activity also can be stimulated by 
several growth factors (e.g. vascular endothelial growth factor [VEGF], platelet derived growth 
factor [PDGF], bone morphogenetic protein [BMP]-4), cytokines (e.g. TNF-α, transforming 
growth factor [TGF]-ß), and metabolic factors (e.g. insulin, glucose) 
85-87
.  In fact, even broader 
environmental agonists of Nox activity including mechanical forces, sheer stress, and conditions 
of hypoxia and reoxygenation exist 
85
.   
 
The ROS generated by the cardiovascular Noxes exert effects on the cell by causing reversible 
oxidation of reactive cysteine residues located on target molecules 
77, 100
.  One of the main targets 
of Nox-derived ROS is the family of protein tyrosine phosphatases (PTPs) such as the SH2 
domain-containing phosphatases, SHP-1 and SHP-2.  These enzymes dephosphorylate tyrosine 
residues and alter signal transduction pathways driven by a wide-array of protein kinases 
77, 88
.  
Interestingly, some kinases (e.g. PKB, PKC, mitogen activated protein kinases [MAPKs]) and 
transcription factors (e.g. activator protein [AP]-1, nuclear factor [NF]-κβ, hypoxia inducible 
factor [HIF]-1) also are redox-sensitive, exponentially magnifying the signaling capacity of ROS 
in the cell.  More direct effects of ROS include their ability to alter the function of enzymes such 
as MMPs, ion channels, and receptors 
85
.  Therefore, it is not surprising that physiological ROS 
regulation and signal transduction have become topics of great interest over the last decade. 
 
In general, ROS signaling is implicated in a range of cell events including cell proliferation, 
migration, and differentiation 
86, 89, 94, 101
.  At toxic levels, however, ROS are known to induce 
programmed cell death 
86
.  While the Noxes are present in a variety of cell systems, the 
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vasculature provides a system in which roles of the specific Nox isoforms are well established.  
In the vasculature, Nox1 exerts its effects on VSMC migration, proliferation, and matrix 
formation 
93
 while Nox2 plays a more prominent role in endothelial cell function and neointimal 
formation 
102-105
.  Nox4 has broader implications, affecting VSMC growth and migration as well 
as inducing cardioprotection following injury 
98, 106, 107
.  Interestingly, divergent subcellular 
localization of the Noxes is thought to facilitate their ability to exert these specific effects and 
mediate distinct cellular functions 
77, 108
.   
 
In the heart, the Noxes are involved in calcium signaling, contractility, and even the detrimental 
effects of LV remodeling following infarct 
85
.  In fact, Nox knock-out mice suggest a negative 
role for Nox2 following myocardial ischemia 
109, 110
 and a potential beneficial role for Nox4 
during periods of chronic pressure overload 
107
.  Overexpression of Sod1 also was demonstrated 
to provide functional benefit following MI, suggesting that overall redox change is an important 
modulator of cardiac repair 
111
.  However, isoform specific roles in cardiac cell maturation and 
function still are being teased apart as will be discussed further in the next section. 
1.4.3 Redox Regulation of Cardiac Differentiation 
Redox regulation of cardiac differentiation has been well studied in ESCs where a structured 
model of cardiogenesis exists and results in spontaneously beating cardiomyocytes within EBs 
after 7 to 8 days of culture.  By faithfully recapitulating the time course of embryogenesis, this 
system provides a good in vitro model for studying the effects of redox balance and ROS 
generation on the regulation of cardiomyocyte growth and differentiation.  Using this system in 
murine cells, Sauer, et al. 
112, 113
 first reported a vital role for ROS in cardiomyogenesis.  
Utilizing electrical field 
112
 and cardiotrophin-1 
113
 stimulation of ROS generation, the group 
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demonstrated a clear link between ROS activation and subsequent mesodermal development and 
cardiac differentiation by ESCs.  Similar cardiogenic outcomes were obtained by applying low 
doses of H2O2 to the cell culture 
114
.  Interestingly, long-term exposure to higher doses of ROS 
was cytotoxic, suggesting a dose dependent mechanism of action.  The theory of ROS as critical 
modulators of ESC-derived cardiomyogenesis has since been confirmed during stimulation with 
several other agonists including peroxisome proliferator activated receptor (PPAR)-α 115 as well 
as in cardiac differentiation by human ESCs 
116
.   
 
In search of the mechanisms by which ROS exert their effects on cardiomyocyte generation, 
several known targets of ROS were evaluated for their participation in the processes of cardiac 
commitment and differentiation of ESCs (Figure 1.2) 
117
.  Of the kinases, phosphatidylinositol 3-
kinase (PI3K) was identified as a key activator of Nox and the subsequent activation of 
extracellular signal regulated kinase (ERK) 1/2 and transcription factor NF-κβ by Nox-derived 
ROS 
112-114
.  Several years later, the ROS dependency of cardiac differentiation further was tied 
to the Nox enzymes when Puceat, et al. 
117, 118
 demonstrated a stage-dependent function of Rac, a 
critical Nox subunit, on cardiac proliferation and differentiation.   Because these studies relied 
heavily on the general Nox inhibitor, diphenylene iodonium (DPI), it remained unclear which of 
the Nox isoforms were required for cardiac differentiation in ESCs.    Therefore, several groups 
went on to investigate the transcript expression of the cardiac Nox isoforms during ESC 
differentiation.  While transient expression of Nox1, Nox2, and Nox4 mRNA was observed 
throughout the differentiation of EBs, it was found that mechanical strain or treatment with 
exogenous ROS induced expression of Nox1 and Nox4, specifically, together with cardiac 
transcription factors Gata4, Nkx2.5, and Mef2c 
119, 120
.  These studies also demonstrated a clear  
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Figure 1.2.  Targets of ROS during Cardiac Differentiation by ESCs 
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redox link to MAPK signaling pathways.  Around the same time, similar results implicating the 
MAPKs and redox sensitive transcription factors in cardiac differentiation were obtained from 
studies using a mouse embryonic carcinoma cell model 
121, 122
.  In 2006, Li, et al. 
123
 proposed a 
more specific model of cardiac differentiation, suggesting Nox4 to be the most prominent Nox 
isoform in cardiac differentiation.  This model established Nox4-derived ROS as a driver of p38 
phosphorylation and the subsequent translocation of cardiac transcription factor Mef2c to the 
nucleus.  Most recently, Nox2 was shown to be upregulated along with Nox4 during ascorbic 
acid induction of cardiac differentiation, suggesting non-redundant roles for the two most 
abundant cardiac Nox isoforms in cardiomyogenesis 
124
.   
1.4.4 Summary 
Because it is clear that Nox-derived ROS play important physiological and pathological roles in 
the cardiovascular system, understanding the mechanistic actions of Nox proteins in resident 
CPCs is critical to enhance current strategies for cell-based therapy.  With genetic modification 
of therapeutic cell populations becoming a popular approach for graft enhancement 
125-127
, 
altering expression levels and/or timing of Nox activity may afford essential control over CPC 
survival and differentiation in the infarct region.   
 
1.5 Statement of Problem and Approach  
 
While it was recently demonstrated that redox effector protein (Ref)-1 plays an important role in 
maintaining the redox balance of cardiac stem cells isolated from the adult rat heart 
128
, very little 
research has been directed at redox regulation of resident CPCs, specifically those marked by the 
receptor tyrosine kinase, c-kit.  Because questions regarding the basic mechanisms that drive 
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CPC self-renewal and differentiation remain largely unanswered, I believe that further 
understanding redox mechanisms, particularly the functions of the cardiac Nox enzymes, and 
how they relate to c-kit
+
 cell function will reveal novel targets for therapeutic action.  Therefore, 
to test the central hypothesis that c-kit
+
 CPCs exhibit a unique redox-related molecular signature 
that confers precursor status, and that this status influences the capacity for cardiac lineage 
commitment, first our laboratory generated a bacterial artificial chromosome (BAC) transgenic 
mouse in which enhanced green fluorescent protein (EGFP) is a fluorescent indicator of c-kit 
promoter activity to isolate and characterize the differentiation potential of neonatal cardiac c-
kit
+
 cells (Chapter 2).  The findings presented in this chapter were generated through the close 
collaboration among four key investigators, Dr. Yvonne Tallini, Dr. Kai Su Greene, Dr. Michael 
Craven, and myself.  It is important to note that the BAC transgenic construct was generated by 
Dr. Kai Su Greene.  Dr. Kai Su Greene also worked with Dr. Yvonne Tallini to perform the 
initial characterization of transgenic founder lines which was nearly complete prior to my arrival 
in the laboratory.  I contributed to the in vivo and in vitro characterization of the lineage status 
and potential of neonatal cardiac c-kit
+ 
cells and Dr. Michael Craven performed the patch clamp 
experiments necessary to determine the electrical physiology of our purported precursor cell 
population.  Utilizing c-kit
+
 cells isolated from the hearts of neonatal c-kit
BAC
-EGFP transgenic 
mice along with redox and molecular biology techniques, next I investigated the redox status of 
c-kit
+
 CPCs and examined the effects of reduced Nox expression on CPC stemness and 
differentiation in vitro (Chapter 3).   
 
The findings presented in Chapter 2 provide strong evidence for the stemness of neonatal c-kit
+
 
CPCs and rationale for their use as a therapeutic population in the treatment of MI.  Chapter 3 
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establishes a link between redox biology and c-kit
+
 CPC cell function and  identifies several 
target molecules including pro-oxidants (Nox2 and Nox4), transcription factors (Gata6 and 
Gata4), and a cytokine (TGF-β1) all of which are involved in c-kit+ CPC lineage specification.  
A final summary of findings, significance of research, and future directions are presented in 
Chapter 4 and leave the reader anticipating additional scientific discovery, which will reveal a 
more precise understanding of the complexities involved in the balance between c-kit
+
 CPC 
status and lineage commitment. 
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CHAPTER TWO: C-KIT EXPRESSION IDENTIFIES CARDIOVASCULAR 
PRECURSORS IN THE NEONATAL HEART* 
 
 
 
 
 
 
 
 
 
 
 
 
*Largely reprinted from Tallini YN, Greene KS, Craven M, Spealman A, Breitbach M, Smith J, 
Fisher PJ, Steffey M, Hesse M, Doran RM, Woods A, Singh B, Yen A, Fleischmann BK, 
Kotlikoff MI. C-kit expression identifies cardiovascular precursors in the neonatal heart. Proc 
Natl Acad Sci U S A. 2009;106:1808-1813 
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analyzed data; and Y.N.T., M.C., M.H., B.K.F., and M.I.K. wrote the paper (modifications from 
original print were written by A.S.). 
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ABSTRACT 
 
Directed differentiation of embryonic stem cells (ESCs) indicates that mesodermal lineages in 
the mammalian heart (smooth muscle, cardiac, and endothelial) develop from a common, 
multipotent cardiovascular precursor.  To isolate and characterize the lineage potential of a 
resident pool of cardiac precursor cells (CPCs), we developed bacterial artificial chromosome 
(BAC) transgenic mice in which enhanced green fluorescent protein (EGFP) is placed under 
control of the c-kit locus (c-kit
BAC
-EGFP mice).  Discrete c-kit-EGFP
+
 cells were observed at 
different stages of differentiation in embryonic hearts, increasing in number to a maximum at 
about postnatal (PN) 2; thereafter c-kit-EGFP
+
 cells declined and were rarely observed in the 
adult heart.  C-kit-EGFP
 +
 cells purified from PN0-5 hearts were nestin-positive and expanded in 
culture; 67% of cells were fluorescent after 9 days.  Purified cells differentiated into smooth 
muscle, cardiac, and endothelial cells, and differentiation could be directed by specific growth 
factors.  CPC-derived cardiomyocytes displayed rhythmic beating and action potentials 
characteristic of multiple cardiac cell types, similar to ESC-derived cardiomyocytes.  Single cell 
dilution studies confirmed the potential of individual CPCs to form all three cardiovascular 
lineages.  In adult hearts, cryoablation resulted in c-kit-EGFP
+
 expression, peaking 7 days post-
cryolesion.  Expression occurred in smooth muscle and endothelial cells in the revascularizing 
infarct, and in terminally differentiated cardiomyocytes in the border zone surrounding the 
infarct.  Similar co-localization of exogenously transplanted c-kit-EGFP
+
/LacZ
+
 cells within the 
injured vasculature also was observed.  Thus c-kit expression marks CPCs in the neonatal heart 
that are capable of directed differentiation in vitro; however, c-kit expression in cardiomyocytes 
in the adult heart following injury does not identify cardiac myogenesis.   
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INTRODUCTION 
 
The process of early heart cell specification from pluripotent CPCs recently has been advanced 
by reports that a common cardiovascular precursor can give rise to smooth muscle cells, 
cardiomyocytes, and endothelial cells through directed differentiation of ESCs in vitro, and when 
these cells are implanted into adult hearts 
2-7
.  Several markers have been reported to identify 
CPCs, including the kinase insert domain protein receptor KDR (also known as Flk-1) 
2, 3, 8
, the 
stem cell factor (SCF) receptor c-kit 
5, 6, 9
, the LIM-homeobox transcription factor islet-1 (Isl-1) 
10-12
, and the cardiac transcription factor Nkx2.5 
5, 13
.  In vitro directed differentiation of ESCs 
suggests that mammalian heart development involves mesoderm specification to a multipotent 
precursor stage.  However such cells have not been isolated from the heart and shown to undergo 
multipotent differentiation in vitro, and Nkx2.5-expressing cells isolated from embryonic day 
(ED) 7.5 and ED 8.5 mouse embryos could not be induced to expand and differentiate 
5
. 
 
Used extensively as a marker to identify adult hematopoietic stem cells (HSCs), c-kit is 
expressed during various stages of cell lineage commitment in germ, mast, stellate, epithelial, 
endothelial, and smooth muscle cells 
14-16
.  Wu, et al. 
5
 isolated c-kit
+
 cells from ED9.5 and 
ED10.5 embryos and demonstrated that these cells express smooth muscle and cardiac genes in 
vitro and differentiate to smooth and cardiac myocytes in xenotransplants.  Here we report the 
isolation and characterization of neonatal c-kit
+
 cells from a transgenic mouse in which EGFP 
expression is placed under control of the kit locus within a BAC.  C-kit-EGFP
+
 cells from PN c-
kit
BAC
-EGFP mouse hearts expand in culture and differentiate in vitro into smooth muscle, 
cardiac, and endothelial cells.  The study of isolated CPCs is likely to provide important 
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information with respect to the genetic status, mechanism of differentiation and commitment, 
and biological potential of these cells. 
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MATERIALS AND METHODS 
 
BAC Targeting and Founder Genotyping  
Two fragments, 564 and 541 base-pairs in length located 5’ and 3’, respectively, to the c-kit 
ATG start codon in Exon 1, were designed and inserted into the pBS-EGFP-pA-FRT-Neo/Kan-
FRT vector by Dr. Kai Su Greene.  This targeting construct was then released by XhoI/SacII 
digestion and electroporated into EL250- RP24-330G11 cells.  Chloramphenicol (12.5 µg/ml) 
and kanamycin (25 µg/ml) resistant clones were genotyped by amplification and sequenced to 
identify homologous recombinants.  The neomycin cassette was removed by L(+)-arabinose 
(0.1%) recombinase induction, leaving only one FRT site.  C-kit
BAC
-EGFP-PA-FRT DNA was 
cesium chloride purified and injected into the pronuclei of zygotes by standard methods.  A 
similar targeting strategy was utilized to generate transgenic mice with EGFP expression under 
the control of the Connexin 45 (gap junction protein) and Acta2 (smooth muscle specific protein) 
gene loci (A.S. rotation project).  The generation of these two lines is ongoing. 
 
Genotyping of c-kit
BAC
-EGFP mice was performed using primer pairs BefArm1/EGFPR1 
(BefArm1:GCAGGTGGAGAAACTGAGCATG; EGFPR1: CCAGGATGTTGCCGTCCTCCT) 
yielding a 1095 base-pair product.  Cycling parameters were: 2 minutes at 94ºC; (30 seconds at 
94ºC, 30 seconds at 57ºC, 1 minute 10 seconds at 68ºC) x40; 10 minutes at 68ºC; hold at 4ºC.  
Newborns (PN0-5) also were screened for EGFP expression using a KL2500 cold light source 
(Schott Fostec) and safety glasses covered with Wratten filter #12 (Kodak).  For transplant 
studies, c-kit
BAC
-EGFP homozygote mice were crossed with a commercially available Rosa26-
LacZ reporter line in which LacZ is knocked into the ubiquitous Rosa locus.  All procedures 
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were approved by Cornell Institutional Animal Care and Use Committee and adhered to the 
standards published in Guide for the Care and Use of Laboratory Animals. 
 
Embryos and Adult Hearts 
Whole embryos [14.5 and 18.5 days post coitus (dpc)] and excised PN2 or 6-16 week old adult 
hearts were fixed with 4% PFA or Stefanini solution, preserved with 20% sucrose, frozen, and 
cut into 8-10 µm sections.  Cryosections were prepared and examined for EGFP expression or 
immunostained using primary antibodies directed against α–actinin (Sigma-Aldrich), -smooth 
muscle actin (SMA) (Sigma-Aldrich), CD45 (Lab Vision), GFP, Flk-1, or platelet endothelial 
cell adhesion molecule (PECAM)1/CD31 (all from BD Pharmingen).  All primary antibodies 
were visualized by appropriate secondary Cy3- or Cy5-conjugated donkey antibodies (Jackson 
ImmunoResearch Laboratories).  Nuclei were stained with Hoechst 33258 (Sigma).  Heart 
sections were imaged using a ProgRes C10+ (Jenoptik) camera connected to a Leica MZ16F 
stereo-fluorescence microscope or an AxioCamMRm camera connected to a Zeiss Axiovert 200 
microscope. 
 
Cell Morphometry 
To calculate the total number of cells per neonatal heart, 7-13 sections from each heart (n=6) 
were imaged with a 20X objective and the total number of Hoechst stained nuclei was 
determined automatically using AxioVision AutMess Software (Zeiss).  The number of EGFP
+
 
cells was determined by manually counting the nuclei of green cells.  Cell numbers were 
extrapolated to the total amount of heart sections, correcting for overlap based on the average 
nuclear size.   
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Fluorescence Activated Cell Sorting (FACS) and Culturing Parameters 
Following dissociation, cells were resuspended in proliferation media (see below) containing 
20% fetal bovine serum (FBS) and maintained in an incubator at 95% O2/5% CO2 and 37 ºC 
until ready for FACS.  Cell suspensions from neonatal c-kit
BAC
-EGFP mice cardiac isolations 
were analyzed and sorted by flow cytometry on a Becton Dickinson Biosciences FACS Aria.  
EGFP was excited by a 488 nm laser and emission was collected in a fluorescein isothiocyanate 
(FITC) channel using a 502 longpass dichroic mirror and a 530/30 bandpass filter.  A parent 
population of cells that represented only whole cells gated to exclude debris by forward and side 
scatter first was determined.  Autofluorescent cells were then identified as cells with a high 
phycoerythrin (PE) 585/42 to 530/30 signal ratio and excluded by gating.  The total EGFP
+
 heart 
cell population (tEGFP) was identified as those cells with signal exceeding the Gaussian 
distribution of heart cells obtained from transgene negative littermates.  A high EGFP expressing 
subgroup (sEGFP) was identified as those cells having a signal >5-fold above control, a 
population that comprised on average the brightest 5% of cells.  Cells were sorted at 65 psi 
through a 70 µm nozzle oscillating at 87 Hz, into proliferation media (see below).  Cell viability 
was evaluated by propidium iodide (PI) exclusion and averaged 92% pre-FACS and 78% post-
FACS.  
 
Cells were plated on Lab Tek 8-well chambered cover glass slides (BD Biosciences) pretreated 
with 0.1% gelatin (Chemicon International), plated at a density of 80,000-160,000/cm
2
 or 8,000-
20,000/cm
2
, and cultured for 2-3 days in proliferation media, containing F12K media (Gibco), 
5% FBS (Chemicon International), 10 ng/mL basic fibroblast growth factor (bFGF; Sigma-
Aldrich), 10 ng/mL leukemia inhibitory factor  (LIF; Chemicon International), and 1% 
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penicillin/streptomycin  (Gibco).  Thereafter, cells were switched to basic media containing 
DMEM/Ham’s F12 (1:1) (Gibco), B27 Supplement (Gibco), 10 ng/mL bFGF, 20 ng/mL 
epidermal growth factor (EGF; Sigma-Aldrich), 10 ng/mL LIF, and 1% penicillin/streptomycin 
until the day of the experiment 
6, 10, 17
.  To induce smooth muscle differentiation 5 ng/ml of 
transforming growth factor-β1 (TGF-β1; R&D Systems) was added to the basic media that in 
some experiments lacked LIF 
18
; to promote endothelial cell differentiation the basic media was 
altered by removal of B27, EGF, and LIF and supplemented with 10 ng/ml vascular endothelial 
growth factor (VEGF; PeproTech Inc.), 5 U/ml of heparin sodium (Baxter Healthcare 
Corporation), and 5% FBS 
19
. 
 
For single cell expansion experiments, cells were diluted in proliferation media (see above) to 
yield one cell/well and plated on 96-well cell culture plates (Corning) that were pretreated with 
0.1% gelatin.  Three days post-plating, individual wells with EGFP fluorescent single cells were 
identified using a Nikon Eclipse TE300 inverted microscope (GFP excitation 470/20; GFP 
emission 510/20) and maintained in proliferation media for three weeks. 
 
Electrophysiology  
After 2-3 days in proliferation media, approximately 20% of the cells began to spontaneously 
contract and relax.  Glass slides or 35 mm Nunc culture dishes containing sEGFP cells were then 
placed in a specially designed, sealed chamber, and mounted on a Nikon Eclipse TE300 
microscope for patch clamping by Dr. Michael Craven.  Current recordings were made using the 
Amphotericin B (300 µg/ml) perforated patch clamp method 
20
.  Patch pipettes were pulled from 
filamented borosilicate capillary glass (TW 150 F4, World Precision Instruments) to a tip 
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diameter of 1-1.5 µm and a resistance of 3-5 MΩ using a P-87 Flaming/Brown micropipette 
puller (Sutter Instrument Co.).  Patch pipettes were tip-filled by briefly dipping them into pipette 
solution (in mM: 133 KCl, 1 MgCl2, 3 EGTA, 1 CaCl2, 10 Hepes) and then back-filled with the 
Amphotericin B containing pipette solution.  After gigaseal formation, experiments were 
initiated once access resistance fell to 10-20 MΩ.  
 
Voltage and current clamp protocols were applied with an Axopatch 200B patch clamp amplifier 
(Axon Instruments) interfaced to a computer by a Digidata 1200 series AD/DA converter (Axon 
Instruments).   During experiments, cells were continually superfused with Hank’s solution (in 
mM: 140 NaCl, 3 KCl, 2 CaCl2, 2 MgCl2, 10 Hepes, 10 glucose) using a solution heater and 
controller (SHM-6, TC344 Warner Instruments Corp.).  The solution switching dead space time 
was approximately 5 seconds.  All experiments were performed at 37 
o
C.  Patch clamp data was 
analyzed offline using Clampex 8.2 (Axon Instruments) and Prism 4 (Graphpad Software Inc.). 
 
Immunocytochemistry  
Individual Markers Co-Labeled with GFP 
Cells cultured on 8-well cover glass slides or in 96-well plates, along with positive control tissue 
slides, were fixed in 4% PFA for 20 minutes at 25 ºC, rinsed 3 times with 0.01 M phosphate 
buffered saline (PBS), and stored at 4 ºC until immunostaining was performed.  Cells and control 
tissues were permeabilized for 5 minutes (2 minutes for PCNA [proliferating cell nuclear 
antigen] and CD31) with 0.01 M PBS 0.05% Triton-X (0.2% for PCNA), and blocked for 1 hour 
with normal mouse IgG (M.O.M. labeling kit, Vector Laboratories) followed by 10% normal 
donkey serum for 15 minutes at room temperature (RT).  Primary antibodies were combined in 
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tris buffered saline (TBS)/M.O.M. buffer; antibodies and dilutions were: mouse anti--SMA 
(1:20, Dako, M0851), mouse anti-PCNA (1:5, Dako, MO879), rat anti-nestin (1:5, Chemicon, 
MAB353), mouse anti-Troponin T (cTnT) (1:200, Neomarkers, Ab-1 13-11), mouse anti-Isl-1 
(1:50, Developmental Studies Hybridoma Bank), or rat anti-PECAM1/CD31 (1:5, BD 
Pharmingen, #550274) combined with rabbit anti-GFP (1:5, Chemicon).  The combined 
antibodies were applied for 25 minutes at 37 
o
C and 40 minutes at RT (Note: CD31 co-labels 
were incubated 30 minutes at 37 
o
C with CD31 antibody before adding combined antibodies).  
To detect GFP, all samples were washed and incubated with FITC donkey anti-rabbit IgG H&L 
(1:80, Jackson ImmunoResearch Laboratories) diluted in TBS at RT for 20 minutes and 
protected from light.  They were then washed and incubated with Texas Red donkey anti-mouse 
IgG H&L (1:80, Jackson ImmunoResearch Laboratories) diluted in TBS M.O.M. buffer for 15 
minutes to detect α-SMA, PCNA, nestin, or cTnT, while CD31 co-labels were incubated with 
biotinylated donkey anti-rat (1:50, Jackson ImmunoResearch Laboratories) followed by 
Streptavidin Texas Red (1:200, Vector) diluted in TBS for 20 minutes at RT.  Stained cells and 
sections were mounted with Vectashield DAPI (Vector).  
 
α-SMA or cTnT Co-Labeled with CD31 
For co-labeling mouse anti--SMA or cTnT with rat anti-CD31, the mouse antibodies were 
detected with AMCA donkey anti-mouse IgG H&L (1:40, Jackson ImmunoResearch 
Laboratories) diluted in M.O.M. buffer for 15 minutes at RT and protected from light.  CD31 
was detected with biotin/Streptavidin Texas Red as in the previous protocol, and DAPI 
counterstaining was omitted. 
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CD117 Co-Labeled with GFP 
Co-labeling with  rabbit anti-GFP (1:5) and goat anti-CD117 (1:30, R&D Systems) followed a 
similar protocol except that cells were incubated for 10 minutes with TBS 0.2% Triton-X to 
permeabilize, M.O.M. blocking was omitted, and cells were blocked with 10% normal donkey 
serum with 10% nonfat dry milk.  Antibodies were diluted in TBS 0.05% Triton-X and incubated 
1.5 hours at 37 
o
C.  CD117 was detected with biotinylated donkey goat (1:100, Jackson 
ImmunoResearch Laboratories) and Streptavidin Texas Red (1:200).  
 
α-SMA Co-Labeled with cTnT 
For co-labeling with mouse anti-α-SMA and mouse anti-cTnT cells were washed in 0.01 M PBS 
and permeabilized for 5 minutes with 0.01 M PBS 0.05% Triton-X.  On Day 1, cells were 
blocked with normal mouse IgG M.O.M. labeling kit for 1 hour, per instructions, followed by 
10% donkey serum/2X casein for 15 minutes at RT, and M.O.M. buffer for an additional 5 
minutes.  Mouse anti-cTnT primary antibody was diluted 1:150 in PBS/M.O.M. buffer and 
applied for 25 minutes at 37 
o
C and 40 minutes at RT.  Texas Red conjugated donkey anti-mouse 
IgG H&L min X secondary antibody (1:80, Jackson ImmunoResearch Laboratories) diluted in 
M.O.M. buffer was incubated on the slides for 20 minutes at RT and protected from light. The 
fluorescent slides were washed and stored overnight in distilled water.  On Day 2 the cells were 
blocked 15 minutes with 10% goat serum, again blocked with normal mouse IgG, rinsed and 
incubated with goat mouse fragments (1:50, Jackson ImmunoResearch Laboratories) for 30 
minutes at 37 
o
C and washed.  Mouse anti-α-SMA antibody was applied at 1:20 in M.O.M. 
buffer as above.  After several rinses, slides were incubated with AMCA blue conjugated donkey 
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anti-mouse IgG H&L min X (1:40, Jackson ImmunoResearch Laboratories) for 20 minutes in the 
dark.  Cells were washed several times with PBS and mounted with Vectashield (Vector). 
 
Controls and Imaging 
Normal mouse IgG (Santa Cruz Biotechnology), rat IgG, or goat IgG (Vector) combined with 
normal rabbit IgG (Vector), at final dilutions (μg/ml) equivalent to corresponding primary 
antibodies served as negative controls.  Mouse tissue including embryo and adult stomach and 
esophagus were fixed and stained along with cultured cells to validate primary antibodies in 
appropriate cell types.  Images were obtained by confocal microscopy (Zeiss 510 Meta Scanning 
Confocal Microscope), a Kodak DCS 460C camera coupled to an Olympus Provis microscope, 
or a Retiga 2000R camera coupled to a Leica DMI 6000B microscope.  
 
Cryoablation and Cell Transplant   
Adult, 8-12 week old, male c-kit
BAC
-EGFP mice underwent cryoablation surgery by Dr. Michele 
Steffey 
21, 22
.  Mice were anesthetized with 2-3% isoflurane and intubated by suspending them on 
a specially designed platform at a 45 º angle and using a 2 cm PE-90 catheter attached to the base 
of a needle for insertion into the trachea 
23
.  Immediately following intubation, mice were placed 
on a warming pad and connected to a ventilator set at 100-120 breaths/minute with a tidal 
volume between .2 and .5 ml.   Mice were kept anesthetized using approximately 1% isoflurane.  
After hair removal and sterilization of the surgical area, a thoracotomy was performed and a 
retractor was used to expose the apex of the heart.  Next, a liquid nitrogen cooled 3 mm copper 
probe was placed against the left ventricle for 10-20 seconds 2-3 times and a chest drain was 
inserted in the pleural space.  The chest wall, muscle layer, and skin were closed with Ethicon 6-
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0 suture and the pneumothorax was drained prior to removal of the chest drain.  Mice were 
extubated and allowed to recover on a warm surface.  They were administered ketoprofen (5 
mg/kg) and ceftazidime (25 mg/kg) for 2 days post-operatively.  Mice were euthanized for 
experiments at specific time points.   
 
For transplant studies, c-kit-EGFP
+
/LacZ
+
 cells were isolated from c-kit
BAC
-EGFP/Rosa26-LacZ 
neonatal mouse hearts as described above on the day of surgery.  150,000-200,000 sorted c-kit-
EGFP
+
/LacZ
+ 
cells were separated into sterile 1.5 ml centrifuge tubes and pelleted.  Cells were 
then resuspended in 10 µl sterile saline/trypan blue for two 5 µl injections into the peri-infarct 
region of C57Bl/6 adult mice.  Injections were performed using a 29G needle connected with 
polyethylene tubing to a 10 µl Hamilton syringe and the injections were visually verified by 
trypan blue 
21
.  Control animals were injected as above with vehicle (sterile saline/trypan blue) 
alone. 
 
Data Analysis 
Data were analyzed with SigmaPlot/SigmaStat/Graphpad Prism 4 software using one-way 
Analysis of Variance with Tukey’s post-hoc comparisons or a Student’s t-test.  Summary values 
are mean ± SEM.   Differences were accepted as statistically significant with p<0.05. 
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RESULTS 
 
Generation of C-kit
BAC
-EGFP Mice 
To facilitate the study of heart precursors known to express c-kit 
5, 6, 9
, Dr. Kai Su Greene 
inserted the EGFP coding sequence in frame at the start codon of c-kit (1
st
 exon) 
24
 within a 186 
kb BAC by recombineering methods (Figure 2.1A) 
25
.  A founder line was identified by a 1.1 kb 
PCR amplicon that included c-kit and EGFP DNA (Figures 2.1A-B).  Neonatal c-kit
BAC
-EGFP 
pups displayed intense skin fluorescence consistent with the expression of c-kit in melanocytes 
(Figure 2.1C) 
16
, and were easily distinguished from non-transgenic wildtype (WT) littermates 
using a hand held fluorescent light source and filtered goggles (see Materials and Methods).  In 
adult mice strong c-kit-EGFP fluorescence was observed in a variety of organs in a pattern 
consistent with endogenous c-kit expression (Figure 2.1D); expression was observed in 
interstitial cells of the intestines and stomach, muscle layer of the uterus, and testis.  C-kit-EGFP 
fluorescence was detected by immunohistochemistry in Leydig cells and outer layer 
spermatogonium in the testis, in basket and stellate cells in the molecular layer of the cerebellum, 
and within the hippocampus (Figure 2.1E), consistent with the cell-type specific expression of c-
kit in these tissues 
26, 27
.  As expected from a genetic strategy in which the endogenous locus was 
not altered, c-kit
BAC
-EGFP mice display no apparent phenotype and transmit the transgene in a 
Mendelian ratio; the line is registered with the Mouse Genome Informatics (MGI) as Tg(RP24-
330G11-EGFP)1Mik, number 3760303. 
 
Spatial and Temporal Expression of EGFP in the Heart 
The expression pattern of c-kit-EGFP fluorescence was analyzed in heart sections from 
embryonic [14.5 and 18.5 dpc], PN2-3, and adult c-kit
BAC
-EGFP mice.  Fluorescent cells were  
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Figure 2.1.  Generation and Evaluation of C-kit
BAC
-EGFP Mice.   
A) BAC targeting strategy placing EGFP in frame at the c-kit initiation codon; Neo cassette 
was removed before DNA injection.  Arrows indicate PCR genotyping primers.  B) 1.1 kb 
PCR product in founder (Lane 1); water and WT controls shown in Lanes 2 and 3; 1kb DNA 
ladder in Lane 4.  C)  Bright field (left) and fluorescent (right) images of PN0 c-kit
BAC
-EGFP 
pups.  D)  C-kit-EGFP expression in adult tissues shows predicted pattern of expression.  E)  
Immunolocalization of c-kit-EGFP in Leydig and outer region of spermatogonium (arrow) in 
adult testis, stellate and basket cells in the molecular layer of the cerebellum, and selective 
hippocampal neurons.  Scale bars: C, 1 mm; D, testis 1 mm, others 100 µm; E, testis 25 µm, 
brain 50 µm. *A.S. contributed to c-kit
BAC
-EGFP mouse husbandry, genotyping by 
fluorescence, cryosectioning, and microscopy.  A.S. also was involved in the design of two 
additional BAC transgenics (Connexin 45 and Acta2) not described here. 
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observed in the atrial and ventricular walls of 14.5 dpc mice (Figure 2.2A, top) and by 18.5 dpc 
discrete areas of c-kit-EGFP
+
 cells could be detected within the thickening chamber walls (data 
not shown).  The total number of c-kit- EGFP
+
 cells increased as the heart expanded in size, 
reaching a maximum shortly after birth (PN2-3; Figure 2.2A, middle).  Thereafter, the number 
declined rapidly and c-kit-EGFP
+
 cells only occasionally were observed as mononuclear cells 
within the vascular compartment, or rarely as striated myocytes within the cardiac interstitium, in 
adult mice (Figure 2.2A, bottom).  In the PN heart, c-kit-EGFP
+
 cells were observed in the 
atrioventricular region (Figure 2.2C), in the atrial and ventricular walls (Figure 2.2A), and the 
epicardial border, where intensely staining cells often were observed.  C-kit co-expression was 
examined by dual immunolabeling of heart sections (Figure 2.2B) and by immunodetection of c-
kit in cells sorted by EGFP fluorescence.  The coincidence of anti-EGFP and anti-CD117 
staining was >90% within clusters (Figure 2.2B), but isolated cells often only stained with one of 
the two antibodies (approximately 45% coincidence).  The latter result may be due to differences 
in protein half-life, technical issues related particularly to the CD117 antibody, or incomplete 
transcriptional fidelity of the c-kit transgene.  
 
We examined the lineage and developmental status of c-kit-EGFP
+
 cells within the postnatal 
(PN2-3) heart by immunostaining in tissue sections that retained EGFP fluorescence.  In the 
atrioventricular region, concentrated clusters of c-kit-EGFP fluorescent cells were observed at 
various stages of cardiovascular development (Figure 2.2C).  Some cells co-stained with -
actinin and displayed early cardiac morphology whereas smaller, elongated -actinin negative 
cells that co-stained with Flk-1, the VEGF receptor 2, which marks ESC-derived CPCs 
2, 3, 8
 also 
were observed (Figure 2.2D).  The latter group included clusters of cells co-expressing the   
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Figure 2.2.  EGFP Expression in C-kit
BAC
-EGFP Mouse Hearts.   
A) C-kit-EGFP expression in the heart wall of 14.5 dpc embryo (fluorescence) and PN3 
(immunostaining) neonates.  In the adult heart only rare immunostained cells were observed.  
Control - no 1
o
 antibody.  B)  EGFP/c-kit expression concordance.  Anti-EGFP (green); Anti-
CD117 (red).  Note lack of co-expression (top) and co-localization within a niche (bottom).  
C) Native c-kit-EGFP expression in the atrioventricular region of a PN2 heart.  D) Some cells 
co-expressed Flk-1 and c-kit-EGFP.  E) Some c-kit-EGFP
+
 cells co-expressed PECAM1, 
indicating endothelial commitment.  Very bright c-kit-EGFP expressing cells commonly were 
observed in the epicardium; these cells co-expressed the hematopoietic lineage marker, CD45.  
F) c-kit-EGFP
+
 cells in the atrioventricular region showing a gradient of EGFP expression, 
from less differentiated bright cells (arrows), to less fluorescent striated cells.  Abbreviations:  
A, atrium; AV, atrioventricular region; and V, ventricle.  Hoechst staining is shown in blue 
for B, D, E and F.  Scale bars: A, 14.5 dpc 50 µm, others, 25 µm; B, 10µm; C,  50 µm ; D, 25 
µm,  blow-up, 10 µm; E left 25 µm, middle  20 µm, blow-up 5 µm; and F,  25 µm.  *A.S. 
contributed to tissue harvest, cryosectioning, and microscopy.   
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endothelial lineage marker PECAM1 (Figure 2.2E, left).  Intensely fluorescent cells also were 
observed at the epicardial border, which were CD45 positive, indicating hematopoietic lineage 
(Figure 2.2E, middle and right).  In some clusters a gradation from less differentiated and more 
intensely fluorescent, to more striated and weakly fluorescent cells, was observed (Figure 2.2F).  
Quantitative morphometry indicated that the more intense staining epicardial cells represented 
0.101±0.004% of all heart cells (3,373±330/heart), whereas non–epicardial c-kit-EGFP+ cells 
characterized 0.46±0.14% of all cells (16,044±6,343/heart).  Thus, we estimate that c-kit-EGFP
+
 
cells constitute less than 1% (0.56±0.16; n=6) of all cells in the neonatal mouse heart.  Taken 
together, these results indicate that the c-kit-EGFP
+
 cell population includes CPCs in several 
stages of development and lineage commitment. 
 
Expansion and Differentiation of Neonatal C-kit
+
 Cells In Vitro  
To isolate c-kit-EGFP
+
 expressing cells and determine their potential to differentiate into 
multiple cell lineages we optimized a dissociation protocol adapted from Worthington’s 
Neonatal Cardiomyocyte Isolation System and sorted cells from pooled PN0-5 c-kit
BAC
-EGFP 
hearts.  C-kit-EGFP
+
 cells could be distinguished by FACS from background fluorescence of 
non-transgenic cells, although there was some overlap at the low end of EGFP expression, as 
shown by the comparison of fluorescence histograms of heart cells from c-kit
BAC
-EGFP and WT 
littermates (Figure 2.3A).  Using a gate that captured cells 5-fold brighter than the mean 
fluorescence intensity, sEGFP cells could be obtained that included only c-kit-EGFP
+
 cells 
(Figure 2.3A).  In some experiments the tEGFP was obtained and c-kit-EGFP
+
 cells 
distinguished from non-expressing EGFP cells by epifluorescent microscopic examination, 
whereas in others the sEGFP fraction was used.  The total number of sEGFP cells/heart averaged  
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Figure 2.3.  Isolation and Expansion of FACS Cardiac C-kit-EGFP
+
 Cells.   
A) Representative FACS from PN c-kit
BAC
-EGFP and WT littermate hearts.  WT and EGFP 
histograms are normalized to the same peak maximum.  tEGFP population overlaps with 
brightly autofluorescent WT cells; sEGFP identifies a pure c-kit-EGFP
+
 population of cells 
that are 5 times brighter than background fluorescence.  B) Morphometry and FACS estimate 
of total number of c-kit-EGFP
+
 cells in neonatal hearts.  C) C-kit-EGFP expression and 
PCNA (red) staining indicates cycling in sEGFP cells cultured for 9 days in basic media.  
Arrow indicates punctuate PCNA staining.  D) C-kit-EGFP expressing cells at 24 hours (left) 
and 9 days (middle) post-FACS.  Note differences in cell size and shape.  At right, tEGFP 
cells plated on feeders expand rapidly (3 days) in a network pattern.  E) Merged brightfield 
and fluorescent image taken after 1 day in culture of tEGFP cells in a cluster.  F) Images 
taken from the same field of view 9 days (left) and 16 days (right) post-sEGFP plating in 
basic media showing expansion of cells.  A small population of cells at both 9 and 16 days are 
no longer fluorescent.  G) Distribution of committed cells 24 hours post-FACS (tEGFP cells).  
Note lack of endothelial cells (PECAM1) and roughly equal distribution of smooth muscle (α-
SMA) and cardiac cells (cTnT).  Nestin staining suggests a sub-set of undifferentiated cells.  
Number of experiments indicated in bars.  H) Co-staining 9-16 days post-FACS (sEGFP 
cells).  I) c-kit (green) cell expressing both α-SMA (blue) and cTnT (red) markers.  J)  Nestin 
(red) and c-kit (green) co-staining in cells cultured for 9 days.  DAPI staining (blue) in H and 
I. Scale bars: C, 20 µm; D, E, F, H, and J, 50 µm; and I, 10 µm.  *A.S. contributed to 
optimization of neonatal cardiomyocyte dissociation protocol and media conditions, 
preparation of cells for FACS, maintenance of cells in culture, preparation of cells for 
immunostaining, microscopy for cell imaging and quantification, and data analysis. 
 68 
 
 
  
 69 
 
 
23,300±3773 (n=7) from FACS analysis, a finding similar to that obtained by counting cells in 
individual heart slices (19,418±7138; n=6) (Figure 2.3B).  
 
tEGFP and sEGFP cell fractions plated on gelatin coated chambered slides rapidly expanded in 
an optimized proliferation media, with individual fluorescent cells undergoing cell cycling as 
indicated by anti-PCNA staining (Figure 2.3C) and the formation of clusters of fluorescent cells 
from isolated cell populations.  Approximately 1 week post-differentiation, a significant 
difference in binucleated cell count between the tEGFP (1.09 ± .25%, n=6) and sEGFP (9.4 ± 
.88%, n=6) cell fractions was observed, suggesting an innate difference in cell division and 
cardiac commitment between the two populations.  Therefore, the sEGFP population was utilized 
for a majority of our studies except where cell number was too low to obtain significant results.  
24 hours after plating, sEGFP cell fractions were 100% fluorescent, consisting of small, brightly 
fluorescent cells containing little cytoplasm, flat cells with a large amount of cytoplasm, or 
spindle-shaped cells; following several days in culture, cells markedly increased in size, often 
forming long processes or extensions that contacted neighboring cells (Figure 2.3D, left and 
middle).  Cells also expanded rapidly when plated on irradiated feeder cells (Figure 2.3D, right).  
The expanding cell population gradually lost expression of EGFP, by 9-16 days after plating of 
sEGFP cells 67±4% (n=3) expressed EGFP and many of these cells co-expressed nestin.  Cells 
expanded as clusters with a central clump of c-kit-EGFP
+
 cells (Figure 2.3E) or as flattened cell 
aggregates (Figure 2.3F).   
 
Cells analyzed 24 hours post-plating lacked expression of HSC markers CD45 and CD34, 
indicating that the prominent epicardial cells did not survive disaggregation.  Surprisingly, the 
 70 
 
endothelial marker PECAM1 barely was detected at 24 hours (0.003±0.003%), although cells did 
induce expression after several days in culture.  Another endothelial marker, Von Willebrand 
Factor (vWF) also was undetectable at 24 hours post-plating.  While cells were negative for 
microfilament marker, sarcomeric actin, approximately 1/3 of the cells did express smooth or 
cardiac muscle specific proteins at 24 hours (39±13% and 30±4%, respectively, Figure 2.3G).  
Not surprisingly, the cells were negative for early skeletal muscle transcription factor, myogenin, 
suggesting specific commitment to the heart musculature.  9-16 days post-FACS several sEGFP 
cells displayed smooth muscle, cardiac muscle, and endothelial markers (Figure 2.3H).  On rare 
occasion α-SMA, cTnT, and c-kit protein were observed in the same cell demonstrating their 
bipotential capacity (Figure 2.3I).  No co-expression of Isl-1 and c-kit-EGFP was observed, 
consistent with separate developmental populations (data no shown) 
10, 11
.  We also did not see 
evidence of Sca-1, another purported CPC marker, in the cells at the 24 hour timepoint.  
However, over 80% of the cells were nestin-positive
 
at 24 hours with greater than 50% of the 
cells retaining nestin expression 9 days after initial plating, further suggesting their precursor 
status (Figures 2.3G and 2.3J) 
28, 29
.  
 
Cardiac Differentiation of C-kit-EGFP
+
 Cells  
Several days after plating in media containing bFGF, many c-kit-EGFP
+
 cells began to 
spontaneously contract.  As cells expanded in culture, contractions spread over clusters of c-kit-
EGFP expressing and non-expressing cells.  Contractions also were observed in single, non-
striated c-kit-EGFP expressing cells after several days in culture (Figure 2.4A), likely indicating 
ongoing myogenesis and the development of a muscle phenotype in culture.  
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Figure 2.4.  Cardiac Phenotype of Spontaneously Beating C-kit-EGFP
+
 Cells.  
A) Representative contractile c-kit-EGFP expressing cell at left in a single frame from a time 
series.  Line through image indicates area used for sequential scans of fluorescence shown at 
right.  Left edge of linescan shows rhythmic contraction of the top left cell extension at 
roughly 2 Hz.  B) Action potentials ranged from nodal-like (top), to more atrial (middle), or 
ventricular (bottom), morphologies.  Note prominent diastolic depolarization phases.  
Networked c-kit-EGFP
+
 cells fired rhythmical burst-like activity, interrupted by periods of 
quiescence accompanied by prominent membrane hyperpolarization.  C) Tetrodotoxin (10 
µM, n=5) or D) Nifedipine (1 µM, n=5), reversibly abolished action potentials.  Scale bar:  A, 
25 µm.  *A.S. contributed to preparation of cells for FACS, maintenance of cells in culture, 
and preparation of cells for patch clamp analysis by Dr. Michael Craven. 
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To determine the electrical phenotype of neonatal c-kit-EGFP
+
 cells, sorted sEGFP cells were 
cultured for 5-7 days and spontaneously contracting cells were examined using patch clamp 
methods by Dr. Michael Craven.  Current clamp recordings revealed spontaneous, rhythmic 
action potentials with characteristics similar to those previously reported from embryonic, and 
ESC-derived cardiac myocytes 
30-32
.  The range of action potential morphologies included nodal, 
atrial, and ventricular characteristics (Figure 2.4B).  Spontaneously depolarizing phase 0 
(pacemaker) currents and stable resting potential were observed, as well as a range of 
depolarization patterns that included atrial or ventricular-like plateau phases and nodal type 
transient depolarizations.  Phasic electrical activity included both stable depolarization rates and 
more complex, repeated burst-type activity, as observed in embryoid body (EB) differentiated 
myocytes 
33
.  The latter pattern was observed mainly in networked c-kit-EGFP
+
 cells, and only 
occasionally in single c-kit-EGFP
+
 cells.   
 
The ion channel dependence of the action potentials was investigated using known blockers of 
cardiac fast sodium channels (tetrodotoxin, 10 µM) and L-type calcium channels (nifedipine, 1 
µM).  Tetrodotoxin abolished action potentials in a reversible manner (Figure 2.4C), indicating 
the cardiac nature of these currents, as vascular smooth muscle cells (VSMCs) do not express 
voltage-dependent sodium channels and action potentials are tetrodotoxin-insensitive; nifedipine 
also inhibited the action potentials, indicating the importance of L-type Ca
2+
 channels (Figure 
2.4D).  Taken together, these data support the cardiac phenotype of spontaneously contracting c-
kit-EGFP
+
-derived cells. 
 
Lineage Potential of C-kit
+
-EGFP Precursor Cells 
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To determine whether individual c-kit-EGFP
+
 cells are multipotent, we sorted sEGFP cells and 
cultured them for 9-16 days under conditions designed to promote cardiovascular lineage 
differentiation.  Wells were stained for cardiac (cTnT), smooth muscle (-SMA), or endothelial 
(PECAM1) markers and the fraction of positive cells was counted in all wells.  Cardiac 
differentiation was markedly favored in media containing bFGF, with approximately 15% of 
cells expressing the cardiac muscle specific marker cTnT, compared to less than 3% in media 
containing TGF-1or VEGF (Figure 2.5A).  Addition of VEGF to the media enhanced the 
expansion of endothelial and smooth muscle cells, and the latter effect was more potent than that 
observed in TGF-1 media.  TGF-1, which has been reported to promote smooth muscle 
differentiation 
3, 5, 34
, slightly increased the average fraction of -SMA positive cells, but was not 
significant, although there was a significant decrease in cardiac myogenesis.  Several other 
cardiogenic factors including 5-azacytidine, cardiogenol-C, cardiotrophin-1, and 2-
mercaptoethanol were evaluated for their roles in cardiac lineage commitment with little change 
(data not shown).  Taken together, these results demonstrate that c-kit-EGFP
+
 cells from neonatal 
hearts can be manipulated in vitro to selectively expand the three cardiovascular lineages.  
 
As the above results could reflect the induced expansion of pre-committed cells or selective 
differentiation of multipotent precursors, we performed limiting dilution studies to determine the 
fate of individual clonal populations.  A proliferation media containing bFGF and LIF was used 
for these studies, as c-kit-EGFP
+
 cells did not survive in standard ESC media.  Cells were plated 
to yield one cell/well and cultured for 21 days; approximately 15% of the individual cells 
counted on day 3 survived and expanded during the culture period (Figure 2.5B).  Separate 
immunostaining of the expanded populations revealed individual committed cardiac (cTnT),  
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Figure 2.5.  C-kit-EGFP
+
 Neonatal Heart Cells are Cardiovascular Precursors.  
A) Modification of commitment outcomes by addition of specific growth factors.  Number of 
experiments indicated in bars.  B) Clonal expansion showing a single c-kit-EGFP
+
 cell at 24 
hours (left) and the clone after 20 days (right).  C) Immunostaining of clones from a single c-
kit-EGFP
+
 cell after 21 days.  Individual cells showing commitment to all three heart 
lineages.  D) Co-immunostaining of clonal populations demonstrate commitment to cardiac 
(left) or smooth muscle (right) and endothelium in the same clone.  DAPI staining (blue) in C.  
Scale bars: B, C and D, 50 µm.  *A.S. contributed to preparation of cells for FACS, 
maintenance of cells in culture, design of media conditions to alter lineage commitment, 
optimization of serial dilutions, tracking of clonal populations by microscopy, preparation of 
cells for immunostaining, microscopy for cell imaging and quantification, and data analysis. 
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smooth muscle (-SMA), and endothelial (PECAM1) cells amongst cells that did not express 
these markers (Figure 2.5C).  The above result, in which cells of all three lineages were detected 
was repeated in 19 separate dilution experiments.  Moreover, co-staining for -SMA and 
PECAM1 or cTnT and PECAM1 clearly demonstrated smooth muscle and endothelial or cardiac 
and endothelial lineages arising in clonal expansions (Figure 2.5D).   In vitro expansion of single 
clones to all 3 cardiovascular lineages indicates that c-kit-EGFP
+
 cells from neonatal hearts 
include a population of undifferentiated cells similar to ESC-derived CPCs 
3, 5, 11
. 
 
Re-expression and Engraftment of C-kit-EGFP
+
 Following Injury 
To analyze c-kit expression following myocardial injury, surgeon Dr. Michele Steffey induced 
cryolesions in the left ventricle of adult c-kit
BAC
-EGFP mice 
22
 and we analyzed c-kit-EGFP 
expression in and around the infarct region which was identified by Sirius red staining of newly 
formed collagen.  7 days after cryolesion there was a marked expression of fluorescent cells in 
the infarct and within the border zone, with fluorescent cells often associated with vessels within 
the infarcts, and modestly fluorescent striated cardiomyocytes surrounding the border zone 
(Figure 2.6A).  In sham operated mice rare c-kit-EGFP
+
 cells were equally distributed 
throughout the myocardium.  C-kit-EGFP expression increased by day 3 after the lesion, peaked 
at 7 days, and declined at 21 days post-injury, whereas in sham operated hearts no temporal 
pattern of c-kit-EGFP
+
 expression was observed. 
 
C-kit-EGFP
+
 cells within the infarct were found preferentially in the vicinity of, and contributing 
to, blood vessels (Figure 2.6B, left and blow up).  Luminal c-kit-EGFP expressing cells in 
vessels were PECAM1
 
positive (Figure 2.6B, right), whereas the outer cells surrounding larger  
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Figure 2.6.  Re-Expression of C-kit-EGFP Following Injury in the Adult Heart.   
A) Left, Stefanini-fixed heart 7 days post-surgery. Note the large number of c-kit-EGFP
+
 cells 
at the border zone and within the infarcted (darker) area.  Right, rare fluorescent cells in sham 
heart.  B) C-kit-EGFP cells within infarct.  Left image, fluorescence wide-field image of adult 
c-kit
BAC
-EGFP heart 14 days post-cryoablation.  Note fluorescent cells lining vessel.  Right, 
c-kit-EGFP
+
 endothelial cells lining an artery 7 days post-injury are identified by PECAM1 
staining; surrounding smooth muscle cells also express c-kit-EGFP.  C) C-kit-EGFP
+
 
cardiomyocytes at border zone.  Left, fluorescent and non-fluorescent striated 
cardiomyocytes.  Middle and right, clusters of c-kit-EGFP
+
 myocytes at border zone 7 days 
post-infarct. D) Lack of pHH3 in c-kit-EGFP
+
 cardiac myocytes.  Left, c-kit-EGFP
+
 and 
EGFP
-
 myocytes at border zone.  Right, single pHH3
+
 non-myocyte within infarct.  Scale 
bars:  A, left, 360 µm,  right, 280 µm; B) left, 250µm, blow-up 100 µm, right, 10 µm; C, 22 
µm; D, left, 14 µm, right, 16 µm. *A.S. contributed to surgical assistance to Dr. Michele 
Steffey, post-operative care, tissue harvest, cryosectioning, imaging by microscopy, and data 
analysis. 
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vessels stained for α-SMA (data not shown), thus contributing to the endothelium and smooth 
muscle layer of vessels, respectively.  Single endothelial cells formed lumens, consistent with 
early angiogenesis.  Fluorescent cells integrated within vessels still were observed 21 days after 
the lesion.  The bulk of the c-kit-EGFP
+
 cells within the infarct at day 7 were vimentin positive 
(data not shown).  
 
By contrast, the pattern of c-kit-EGFP expression in the border zone of the cryoinfarct was 
markedly different, with modest, but distinct, c-kit-EGFP expression in striated cardiomyocytes 
(Figure 2.6C) and more robust expression in elongated fibroblasts.  EGFP expression in border 
zone cardiomyocytes was confirmed by immunostaining (data not shown).  C-kit-EGFP
+
 
cardiomyocytes did not express phospho-histone H3 (pHH3), a marker of cell proliferation, and 
the number of these cells peaked at day 7 and declined to the level of sham control by day 21 
(Figure 2.6D).  Neither mitotic figures nor immature cardiomyocytes were observed post-
cryoablation.  cTnT positive cells never were observed within the infarct, indicating a lack of 
cardiac myogenesis associated with c-kit expression.   pHH3
+
 fibroblasts and leukocytes were 
observed within the infarct and at the border zone, only about 1% of pHH3
+
 cells were also c-
kit
+
.  Thus c-kit expression is observed in cells associated with the early revascularization and 
fibrosis of the infarcted heart, declining within a few weeks after injury, but is also seen in 
differentiated myocytes.  The latter expression is not associated with myocyte proliferation, 
suggesting caution with respect to the interpretation of the role of c-kit
+
 myocytes in heart repair.  
When c-kit-EGFP
+
/LacZ
+
 cells were transplanted into the peri-infarct region of wildtype mice, 
exogenously delivered c-kit-EGFP
+
/LacZ
+
 cells could be identified even after terminal 
differentiation in and around the ablated myocardium.  In preliminary studies, we observed 
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LacZ
+
 cells in the tunica media region of blood vessels, further supporting a role for c-kit
+
 cells 
in vascular repair and angiogenesis (data not shown).  We did not observe any LacZ staining in 
control animals, ruling out endogenous expression of β-galactosidase in the cardiac region of 
interest.  These studies are on-going in the laboratory. 
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DISCUSSION 
 
The stem cell surface antigen, c-kit, is at the center of an array of cell lineage determinants.  
Recent evidence suggests that within the developing heart a resident population of CPCs exist, 
with the capacity to differentiate into multiple cardiovascular cell lineages 
5
.  C-kit expression 
appears to characterize a developmental stage of one subset of these cardiovascular precursor 
cells 
2
, however studies in mouse 
5
 and human 
3, 4
 ESC-derived precursors suggest that a c-kit 
negative stage precedes commitment.  To examine the role of c-kit expression in CPCs, and to 
facilitate their isolation and analysis, we created BAC transgenic mice in which EGFP is placed 
under the transcriptional control of the c-kit locus, as this genetic strategy can achieve very high 
expression levels and outstanding transcriptional fidelity 
35, 36
. 
 
Previously, minimal promoter or knock-in strategies have been used to mark c-kit expression 
37
, 
but few studies have examined expression in the developing heart.  Bernex and colleagues 
37
 and 
Wouters, et al. 
38
 knocked reporters into the c-kit locus, but did not examine cardiac expression, 
and the dominant nature of the c-kit locus significantly complicates this strategy.  Fransioli, et al. 
39
 reported the development of a transgenic line in which GFP was driven by a minimal c-kit 
promoter construct; similar to our observations, they reported that individual c-kit expressing 
cells were observed in the developing heart and that the concordance of anti-CD117 and anti-
GFP staining was strong but not complete.  Moreover, EGFP labeled cells increased until shortly 
after birth and declined thereafter 
39, 40
. 
 
We now show that embryonic and postnatal c-kit
+
 cells are in a mixed developmental state 
within the developing heart (Figure 2.2), as predicted for a population of cells transitioning from 
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precursor to committed status.  Neonatal c-kit
+
 cells are characterized by the co-expression of 
nestin (Figure 2.3), a marker of a variety of cells with multilineage potential 
28, 29
, and some of 
these cells also express cardiac, endothelial, or smooth muscle commitment markers (Figure 2.3).  
 
C-kit
+
 cells isolated by FACS expanded, while differentiating in culture on feeder cells and 
gelatin coated plates (Figure 2.3).  When plated as a mixed (c-kit
+
 and c-kit
-
 cells) population, c-
kit
+
 cells often formed extended networks next to more compact, contracting cells.  EGFP 
expressing cells also began to contract in culture and when purified to complete homogeneity by 
FACS individual fluorescent cells were shown to contract, further demonstrating the mixed 
differentiation status of c-kit-EGFP
+
 cells.  EGFP expression declined gradually in cultured cells, 
particularly in mixed cultures, indicating the ongoing differentiation of cells in the presence of 
growth factors such as bFGF. 
 
Many of these cells displayed clear cardiac-like action potentials that were sensitive to 
tetrodotoxin and had a marked plateau phase.  However, some cells also displayed more nodal-
like activity without a prominent plateau phase (Figure 2.4).   The presence of cells with mixed 
electrical activity is also a characteristic of ESC-derived cardiomyocytes and the presence of 
multiple ion currents in the same cells appears to be a characteristic of cardiac development 
30, 32, 
41
.  The plateau phase morphology of some action potentials and their inhibition by tetrodotoxin 
establishes the definitive cardiac phenotype of these cells.  VSMCs do not display a 
characteristic action potential feature, it is possible that rhythmically active cells without a 
plateau phase represent this lineage, or alternatively that differentiating smooth muscle cells, 
unlike committed cardiac cells, do not display spontaneous rhythmicity.   
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Following initial plating, a fraction of c-kit
+
 cells stained for either cTnT or -SMA, but despite 
the identification of PECAM1 staining fluorescent cells in the neonatal heart (Figure 2.2), 
adherent cells were not PECAM1 positive after 1 day in culture (Figure 2.3G), whereas after 
several days in culture PECAM1 was readily detected (Figure 2.3H).  This may reflect a failure 
of endothelial-committed cells to attach or partial digestion of the PECAM1/CD31 epitope 
during enzymatic cell dissociation. 
   
Our initial attempts to culture single purified c-kit
+
 cells isolated by FACS resulted in cell death 
in ESC media.  Switching to a media containing bFGF, a growth factor associated with 
mesodermal cell survival, promotion of cell proliferation, and angiogenesis 
5, 42
, produced viable 
cells that expanded and generated differentiated mesenchymal cells in culture.  Wu, et al. 
5
 also 
tried to culture Nkx2.5
+
 cells isolated from 7.5-8.5 dpc embryonic hearts by FACS in similar 
ESC media without success.  The addition of bFGF, which is associated with mesodermal cell 
survival, or other growth factors, appears to be necessary for the propagation of c-kit
+
 cells in 
culture. 
 
To establish the lineage potential of neonatal c-kit
+
 cells, we manipulated growth factors in the 
culture media and examined the proportion of cell displaying evidence of smooth muscle, 
cardiac, or endothelial commitment.  The number of cells expressing cTnT markedly was 
increased by inclusion of bFGF in the culture media, whereas VEGF shifted the differentiation 
profile toward vascular cells, significantly increasing the number of cells expressing -SMA and 
PECAM1 (Figure 2.5A).  Substitution of the growth factor TGF-β1, a known smooth muscle 
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mitogen, did not significantly increase smooth muscle or endothelial differentiation, although it 
did markedly decrease cardiac commitment (Figure 2.5A). 
 
As c-kit-EGFP
+
 cells display various stages of differentiation in the neonatal heart (Figure 2.2), 
the above results could suggest either the presence of multipotent cardiovascular precursors 
within the purified cell population, or the selective survival and expansion of pre-committed 
populations under appropriate in vitro conditions.  To determine whether c-kit-EGFP
+
 cells 
include uncommitted precursors, we undertook a clonal analysis by plating cells at limiting 
dilutions that yielded individual cells within multi-well plates.  The absence of attachment 
factors and conditioning substances resulted in relatively low viability of dilute clones; however 
individual surviving cells were observed to expand into clonal colonies and were probed for 
lineage commitment 21-25 days after plating.  Evidence of commitment to all three 
cardiovascular lineages was observed in these clonal populations, although the great majority of 
cells did not express any lineage-specific markers (Figure 2.5C).  The presence of uncommitted 
cells within these colonies suggests that the results are not simply explained by expansion of a 
previously committed cell, definitive evidence of multilineage potential was obtained by co-
staining of these clonal populations (Figure 2.5D).  Differentiation of individual cells to both 
muscle (smooth and cardiac) and endothelium was observed, definitively establishing the 
multilineage potential of neonatal c-kit-EGFP
+
 cells.  These results are similar to those reported 
by Moretti, et al. 
11
, who clonally amplified Isl-1
+
 cells from ED8-8.5 heart cell cultures, and 
showed that a rare number of these cells differentiated into smooth muscle cells, cardiac 
myocytes, and endothelium.  These Isl-1
+
 and/or Nkx2.5
+ 
cells, isolated from hearts at a 
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markedly earlier stage of development, do not express c-kit 
10
, and our results confirm a lack of 
Isl-1 staining in c-kit-EGFP
+
 cells. 
 
Recent work from Li, et al. 
40
 demonstrated that pressure overload results in augmented 
expression of c-kit in cardiomyocytes.  Such expression could reflect cardiomyogenesis from c-
kit
+
 cells, or could be the result of c-kit re-expression in myocytes subsequent to exposure to 
inflammatory products and mesenchymal stem cell (MSC)-derived cytokines.  We show that c-
kit expression in the adult, injured heart is associated with fibrous and vascular infarct repair, but 
not myogenesis.  C-kit expression is detectable within 3 days post-injury, peaks at 7 days, and 
declines within a 4 week period to near baseline.  C-kit-EGFP
+
 expression in cardiomyocytes 
only was observed in striated, terminally differentiated cells.  The lack of c-kit-EGFP
+ 
myocytes 
within the infarct zone, absence of immature (non-striated) cTnT-positive myocytes, and lack of 
mitotic figures or pHH3 staining in c-kit-EGFP
+
 myocytes indicates that cryoinjury does not 
provoke cardiomyogenesis through activation of c-kit.  Rather, that c-kit re-expression occurs in 
differentiated cardiomyocytes at regions surrounding cardiac injury, activated by local conditions 
such as hypoxia or inflammatory cytokines, as these cells are not seen at remote regions.  Thus, 
rather than unequivocally identifying adult cardiac precursors, c-kit re-expression in adult 
cardiac myocytes appears to play a role in the transcriptional activation of fetal/neonatal genes 
that are induced during cardiac stress 
40, 43, 44
. 
 
In summary, we describe the purification of a population of cells that includes mesodermally-
derived, CPCs, as well as cells in early stages of cardiovascular development.  Our results 
indicate that true CPCs persist through embryonic development and that the PN heart contains a 
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significant number of these cells, which decline rapidly in the first weeks after birth.  Isolated 
CPCs differentiate into rhythmically contracting cell networks, and individual cells display 
complex electrical activity similar to that observed following the directed differentiation of ESCs 
30, 32
.  C-kit-EGFP
+
 cells can be expanded efficiently in vitro, although the multipotency of 
expanded and passaged c-kit-EGFP
+
 cells remains to be demonstrated.  Finally, c-kit-EGFP
+
 
cells are observed transiently in damaged heart tissue, but do not identify prominent re-activation 
of resident CPCs in the adult heart.  Neonatal c-kit-EGFP
+
 cells may prove useful for 
determination of the genetic basis of CPC status and provide a model for the directed 
differentiation of pluripotent cells for cardiac cell-based therapy.   
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CHAPTER THREE: NADPH OXIDASE ISOFORMS DIFFERENTIALLY INFLUENCE 
NEONATAL C-KIT
+
 CARDIAC PRECURSOR CELL STATUS AND 
DIFFERENTIATION 
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ABSTRACT 
 
Heart disease is a leading cause of death in part due to the inability of the adult heart to support 
cardiac myogenesis following large-scale injury.  Cardiac precursor cells (CPCs) are found in 
significant numbers in the neonatal mammalian heart; however, the mechanisms regulating CPC 
function are incompletely understood.  Recently, redox status has emerged as critical in 
modulating stemness and lineage commitment in several precursor cell types, however, little is 
known in CPCs.  NADPH oxidase (Nox)-derived reactive oxygen species (ROS) are key 
components of cardiac signaling and function.  Therefore, I tested the hypothesis that CPCs 
marked by type III receptor tyrosine kinase c-kit (c-kit
+
) exhibit a unique Nox signature that 
confers precursor status, and that alterations in this profile influence lineage specification.  
Dihydroethidium (DHE) microfluorography showed reduced basal ROS formation within early 
postnatal c-kit
+
 CPCs.  Real-time quantitative PCR (qPCR) revealed downregulation of the ROS 
generator Nox2 and its subunit p67
phox 
in c-kit
+
 CPCs under basal conditions, but upregulation of 
Nox2 and Nox4 over the course of differentiation.  Adenoviral silencing of Nox2 and Nox4 
increased expression of CPC markers, c-kit and Flk-1, and blunted smooth and cardiac muscle 
differentiation, respectively.  These changes were accompanied by altered expression of 
transcription factors, Gata6 and Gata4, and the cytokine, TGF-β1.  In conclusion, c-kit+ CPCs 
exist in a low ROS state like other precursor cells, in part due to reduced Nox2 expression and 
increases in Nox2 and Nox4 are important for the differentiation of these cells into smooth and cardiac 
muscle, respectively.  I speculate that these may be novel targets in CPCs which could prove useful 
in cell-based therapy of the heart. 
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INTRODUCTION 
 
Owing in large part to the low regenerative capacity of the adult heart 
1
, coronary heart disease 
(CHD) remains one of the leading causes of death in the developed world.  In 2007, CHD 
accounted for 1 out of every 6 deaths in the United States 
2
.  Evidence from directed 
differentiation of embryonic stem cells (ESCs) and in neonatal mice indicates a significant 
population of cardiac precursor cells (CPCs) at this developmental stage capable of generating 
the three lineages that specify the heart: smooth muscle, cardiac, and endothelial 
3-6
.  
Unfortunately, the extent and capacity of adult CPCs 
7
 to cope with the loss of tissue following 
myocardial infarction or other damage is limited, suggesting that exogenous expansion and 
therapeutic delivery may be necessary to achieve substantial cardiac regeneration.  Recently, it 
has been proposed that redox mechanisms play important roles both in maintaining stemness and 
in mediating lineage commitment of several precursor cell types 
8, 9
.  Collectively, these reports 
suggest that a more reduced environment is conducive to cell survival and cell division, while a 
more oxidized condition favors differentiation and/or apoptosis.   
 
NADPH oxidase (Nox) enzymes are essential components of cardiac redox biology and generate 
reactive oxygen species (ROS) in a highly regulated manner 
10, 11
.  Unlike the neutrophil 
oxidases which release a large “respiratory burst” of superoxide to ward off pathogens, the Nox 
enzymes (Nox1, Nox2, and Nox4) generate lower levels of intracellular ROS which are 
necessary for cell signaling and survival 
10
.  Of these Nox homologues, Nox2 and Nox4 are most 
abundantly expressed in the myocardium 
11
.  While Nox2 and Nox4 knockout mice do not 
demonstrate defects in heart development 
12, 13
, likely due to compensatory mechanisms, recent 
evidence indicates that Nox2- and Nox4- derived ROS play critical roles in cardiovascular cell 
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function.  Nox2 has been linked to neointimal remodeling and neovascularization after hindlimb 
ischemia as well as left ventricular remodeling following myocardial infarction 
14-16
, while Nox4 
has been linked to enhanced myocardial capillary density upon pressure overload as well as 
increased expression of smooth muscle-specific genes during vascular formation from embryonic 
stem cells (ESCs) 
12, 17
.  The Nox enzymes also are implicated in cardiac cell differentiation.  For 
example, Rac, a critical Nox subunit, was found to play an important role in early 
cardiomyogenesis by ESCs 
18
, while stimulation of peroxisome proliferator-activated receptor 
alpha (PPARα) is thought to enhance ESC-mediated cardiomyogenesis via pathways involving 
both ROS and Nox activity 
19
.  The majority of the studies implicating Nox-derived ROS in 
smooth muscle generation and cardiac differentiation have been performed in ESCs 
17-21
.  
However, a recent study linking redox gene Ref-1 to the redox status of adult c-kit
+
 cardiac stem 
cells and their commitment to the cardiac fate suggests that Nox regulation also might be a 
critical modulator of CPC function 
22
.  
 
CPCs can be identified by their surface markers including Sca-1 (a member of the Ly-6 family) 
23
, Flk-1 (a receptor for vascular endothelial growth factor (VEGF)) 
5
, and c-kit (a type III 
receptor tyrosine kinase) 
4, 6, 7
.  Research from our laboratory and others demonstrates that c-kit 
identifies a mesodermally-derived cell population consisting of both precursors that co-express 
Flk-1 and cardiac cells co-expressing α-actinin in the very early stages of lineage commitment 
and development 
4, 6
.  When isolated from the early postnatal (PN) heart, c-kit
+
 cells expand and 
differentiate in vitro into all three cardiac lineages and display morphological characteristics of 
nodal, atrial, and ventricular action potentials 
6
.  With an increased understanding of CPCs and 
their potential in cell-based therapies, elucidating the redox mechanisms that regulate CPC 
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function including the interplay between Nox-derived ROS and CPC lineage commitment is 
critical.   
 
As such, the goal of this study was to test the hypothesis that c-kit
+
 CPCs exhibit a unique Nox 
molecular signature that confers precursor status, and that alterations in this profile influence 
cardiac cell differentiation.  Utilizing genetic tools to selectively manipulate the Nox enzymes of 
early postnatal c-kit
+
 CPCs, my results demonstrate that Nox2 and Nox4 modulate the balance 
between c-kit
+ 
cell precursor and differentiation status.  I found that silencing Nox2 and Nox4 
blunts the differentiation of c-kit
+
 CPCs along the smooth muscle and cardiac lineages, while 
simultaneously increasing the expression of early precursor cell markers and altering the 
expression of transcription factors and cytokines necessary for cardiac lineage specification.  I 
speculate that these redox genes, along with others identified by mRNA PCR arrays, will provide 
novel targets for improving the regenerative capacity of c-kit
+
 CPCs, which eventually may be 
integrated into cell-based therapies for myocardial infarction.     
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 MATERIALS AND METHODS 
 
Animals 
Bacterial artificial chromosome (BAC) transgenic mice in which enhanced green fluorescent 
protein (EGFP) is a transcriptional indicator of c-kit promoter activity (c-kit
BAC
-EGFP) and their 
wildtype (WT) C57BL/6 littermates (ages postnatal (PN) 0-4) were utilized for these studies 
6
.  
C-kit
BAC
-EGFP heterozygote and homozygote transgenic mice were obtained from in-house 
colonies and bred.  C-kit
BAC
-EGFP newborns (PN0-4) were screened for EGFP expression using 
a KL2500 cold light source (Leica) with safety glasses covered with Wratten filter #12 (Kodak).  
All procedures involving the use of animals were approved by the Institutional Animal Care and 
Use Committee at Weill Cornell Medical College in New York, NY and met the standards set 
forth by the NIH Guide for the Care and Use of Laboratory Animals, United States Department 
of Agriculture regulations, and the American Veterinary Medical Association Panel on 
Euthanasia. 
 
Cell Isolation and Fluorescence Activated Cell Sorting (FACS) 
Cardiac c-kit
+ 
cells from PN0-4 heterozygote c-kit
BAC
-EGFP pups, hereafter referred to as 
“freshly isolated c-kit+ cells,”  or total cardiomyocytes from age-matched WT littermates, 
hereafter referred to as “control cardiomyocytes,” were dispersed using a modified version of 
Worthington’s Neonatal Cardiomyocyte Isolation System and isolated by flow cytometry 6, 24.  
FACS was undertaken using a Becton-Dickinson FACSVantage SE at the Flow Cytometry 
Facility at the Hospital for Special Surgery in New York, NY.  For sorting, cells were 
resuspended in a DMEM medium (Gibco) without phenol red containing Stasis
TM
 Stem Cell 
Qualified U.S. Origin Fetal Bovine Serum (2%, Gemini Bio-Products) and sorted into an F12K 
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Nutrient Mixture, Kaighn’s Modification medium (see Culturing Conditions Section) with 20% 
FBS.  Cells were sorted under 13 psi sheath pressure through a 70 µm nozzle.  Cells were gated 
into a parent population using a side scatter area vs. forward scatter area plot.  This parent 
population was then gated to include only single cells using a side scatter width vs. side scatter 
area plot.  Finally, EGFP
+
 cells were identified using a 488 nm excitation laser and two bandpass 
filters (fluorescein isothiocyanate (FITC) 530/30 and phycoerythrin (PE) 575/26).  Total EGFP
+
 
(tEGFP) cells were effectively separated from autofluorescing cells using a final plot, FITC area 
vs. PE area 
6
.  Total cardiomyocytes from age-matched WT littermates were sorted under 
identical conditions and served as control cells. 
 
Culturing Conditions 
Immediately after FACS, freshly isolated c-kit
+
 cells were seeded onto Lab-Tek™ II 4-well 
chamber slides (Nunc) and cultured in a F12K Nutrient Mixture, Kaighn’s Modification medium 
(Gibco) containing Stasis
TM
 Stem Cell Qualified U.S. Origin Fetal Bovine Serum (5%, Gemini 
Bio-Products), bFGF (10 ng/ml, Invitrogen), LIF (10ng/ml, Millipore), and Pen Strep (1%, 
Gibco) 
6
.  For the Nox differentiation timecourse, freshly isolated c-kit
+
 cells were cultured in the 
F12K medium for 3 days and then switched to a Dulbecco's Modified Eagle Medium: Nutrient 
Mixture F-12 (DMEM/F-12) Media (Gibco) supplemented with B27 (2%, Invitrogen), bFGF (10 
ng/ml), LIF (10 ng/ml), EGF (20 ng/ml, Invitrogen), and Pen Strep (1%) 
6
.  Cells were incubated 
in a NAPCO Series 8000 DH CO2 incubator (95% air/5% CO2) at 37 ºC and media was changed 
every 3-4 days.   
 
ROS Detection  
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ROS production was assessed using dihydroethidium (DHE) as an indicator.  For in vitro ROS 
detection, c-kit
+
 cells were cultured at low density for 48 hours.  At this time, cell media was 
aspirated and cells were rinsed twice with warmed DPBS (Gibco).  Cells were then treated with 
2.5 µM DHE (Invitrogen) dissolved in DMSO and diluted in DPBS for 30 minutes at 37 ºC in 
the dark.  Following DHE application, cells were rinsed for 5 minutes and coverslipped using 
Aqua-Mount (Fisher Scientific).  Coverslipped cells were imaged the same day using an Orca-
ER B/W camera (Hamamatsu Photonics) connected to a Zeiss Axioplan 2 microscope.  DHE 
fluorescence intensity was quantified using NIH ImageJ software and expressed relative to c-kit
+
 
cells 
25
.  Background fluorescence was subtracted from the red and green channels.  Next, the 
cell was identified in the green channel and traced using the elliptical function.  This selection 
was then restored onto the corresponding red channel image and pixel number was measured.  C-
kit
+ 
cells were identified as those with bright EGFP fluorescence compared to non-c-kit 
expressing cells within the same well 
26
.  This process was repeated for each field.  In total, 
approximately 12 fields were analyzed (3 fields/well) for each of the 3 biological replicates. 
  
For in vivo DHE microfluorography 
27, 28
, PN0-1 homozygote c-kit
BAC
-EGFP pups were 
anesthetized using hypothermia 
29
 for 3 minutes and injected with DHE (10 µl I.P.; 4 mg/ml; 
dissolved in DMSO and diluted in sterile saline) using a 30 G needle.  After a 1.5-2 hour 
incubation period on a warming pad, pups were euthanized and the heart tissue was harvested.  
Heart tissue was fixed for exactly 1 hour in 4% PFA at 4 ºC and dehydrated overnight in 20% 
sucrose.  Hearts were embedded in OCT and cryosectioned at 8 µm.  Sections were coverslipped 
using Vectashield mounting media for fluorescence (Vector) and imaged the same day on a LSM 
5 Live confocal microscope (Zeiss).  DHE fluorescence intensity was quantified as above except 
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3 directly neighboring c-kit
-
 cells were used for the comparison and areas of the tissue remote to 
the c-kit
+
 clusters were used to account for autofluorescence.  Approximately 5-10 sections per 
neonatal heart were analyzed from a total of 5 biological replicates. 
 
Real-time Quantitative PCR (qPCR) 
RNA was harvested from freshly isolated c-kit
+
 cells and control cardiomyocytes directly after 
FACS or cultured c-kit
+
 cells using an optimized version of the TRIzol (Invitrogen) protocol to 
increase precipitation time in isopropanol.  1-2 randomly selected samples from each RNA batch 
were assigned RIN values by an Agilent 2100 bioanalyzer to determine RNA integrity and all 
samples were reverse transcribed into cDNA using a TaqMan Reverse Transcription Kit 
(Applied Biosystems) and the cycling parameters provided by the manufacturer.  qPCR was 
performed using 8-20 ng of RNA template per well, PerfeCTa SYBR Green FastMix (Quanta), 
gene specific primers (Table 3.1), and an iQ5 Cycler (Bio-Rad) as described 
30
.  Cycling 
parameters were as follows: 10 minutes at 95 ºC; 40 x [15 seconds at 95 ºC, 1 minute at 60 ºC].  
All primers (Table 3.1) were verified by standard and melt curve analyses using RNA isolated 
from ESCs, control cardiomyocytes, and/or PN4 wildtype hearts.  Values were normalized to β-
actin mRNA expression.   
 
Adenoviral Vectors 
Recombinant E1-deleted adenoviral vectors (human Ad serotype 5) encoding siRNA targeted 
against Nox2 (AdsiNox2), Nox4 (AdsiNox4), and EGFP (AdsiCON) have been described and 
characterized previously 
30-33
.  For all adenoviral knockdown studies, c-kit
+
 cells were infected 
on Day 7 of culture (100 pfu/cell, Figures 3.1A-B) and RNA was isolated (see qPCR Section), 
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Table 3.1.  Primers Used in this Study. 
 
     
Transcript from Gene Gene Bank Accession Number Forward primer (5' → 3') Reverse Primer (5' → 3')
Acta2 (α-SMA) NM_007392 ATTGTGCTGGACTCTGGAGATGGT TGATGTCACGGACAATCTCACGCT
B-actin NM_007393 CATCCTCTTCCTCCCTGGAGAAGA ACAGGATTCCATACCCAAGAAGGAAGG
C-kit NM_021099 TCATCGAGTGTGATGGGAAA GGTGACTTGTTTCAGGCACA
Cat NM_009804 AGCGACCAGATGAAGCAGTG TCCGCTCTCTGTCAAAGTGTG
Cygb NM_030206 CCGGGCGACATGGAGATAGA GTCCTCGCAGTTGGCATACAG
Gata4 NM_008092 GAAAACGGAAGCCCAAGAACC TGCTGTGCCCATAGTGAGATGAC
Gata6 NM_010258 TTGCTCCGGTAACAGCAGTG GTGGTCGCTTGTGTAGAAGGA
Gpx4 NM_008162 GTGTGCATCCCGCGATGATT CCCCTGTACTTATCCAGGCAGA
Kdr (Flk-1) NM_010612 TTTGGCAAATACAACCCTTCAGA GCAGAAGATACTGTCACCACC
Klf4 NM_010637 GGTGCAGCTTGCAGCAGTAA AAAGTCTAGGTCCAGGAGGTCGTT
Ncf2 (p67
phox
) NM_010877 AGCTTCTGCTCCTGTCCGAAGAAA AATAAGACCTTGGTCACCCACCGT
Nox1 NM_172203    CGTGATTACCAAGGTTGTCATGCAC GATGCCACTCCAGGAAGGAAATGGA
Nox2 NM_007807  TTCCAGTGCGTGTTGCTCGAC GATGGCGGTGTGCAGTGCTAT
Nox4 NM_015760 GGATCACAGAAGGTCCCTAGCAG GCGGCTACATGCACACCTGAGAA
Prdx2 NM_011563 GGCAACGCAAATCGGAAAG TCCAGTGGGTAGAAAAAGAGGA
Prdx3 NM_007452 GGTTGCTCGTCATGCAAGTG CCACAGTATGTCTGTCAAACAGG
Prdx6 NM_007453 CGCCAGAGTTTGCCAAGAG TCCGTGGGTGTTTCACCATTG
Sod1 NM_011434 AACCAGTTGTGTCAGGAC CCACCATGTTTCTTAGAGTGAGG
Sod2 NM_013671 CAGACCTGCCTTACGACTATGG CTCGGTGGCGTTGAGATTGTT
Sod3 NM_011435 GGTTGAGAAGATAGGCGACAC CGTGGCTGATGGTTGTACC
Tgfb1 NM_011577               GATCCTGTCCAAACTAAGGCTC ACCTCTTTAGCATAGTAGTCCGC
Tnnt2 (cTnT) NM_011619 CAGAGGAGGCCAACGTAGAAG CTCCATCGGGGATCTTGGGT
Vegfa NM_009505 CTTGTTCAGAGCGGAGAAAGC CATCTGCAAGTACGTTCGTTT
Vwf NM_011708 CTTCTGTACGCCTCAGCTATG GCCGTTGTAATTCCCACACAAG
1
0
4
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Figure 3.1.  Nox2 and Nox4 Transcript Levels by qPCR (Nox knockdown verification).  
(A) Nox2 and (B) Nox4 transcript levels analyzed by qPCR in c-kit
+
 cells isolated from PN0-4 heterozygote c-
kit
BAC
-EGFP pup hearts and infected with AdsiCON, AdsiNox2, AdsiNox4, or AdsiNox2/4 for 48 hours.  
n=3/group.  Gene expression was normalized to β-actin.  
1
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protein was harvested (see Western Immunoblot Section), or cells were fixed for 
immunocytochemistry (see Immunocytochemistry Section) on Day 14.  All adenoviral vectors 
were obtained from the Iowa Gene Transfer Vector Core.   
 
Western Immunoblot 
C-kit protein levels were assessed by Western immunoblot performed on c-kit
+
 cells isolated 
from PN0-4 heterozygote c-kit
BAC
-EGFP pup hearts and infected with AdsiCON, AdsiNox2, 
AdsiNox4, or AdsiNox2/4 utilizing SDS-PAGE.  Samples were incubated with polyclonal rabbit 
anti-c-kit antibody (sc-168, Santa Cruz Biotechnology, Inc.; 1:100 in TBS with 3% BSA and .1% 
Tween-20) followed by goat anti-rabbit HRP (sc-2030, Santa Cruz Biotechnology, Inc.; 
1:10,000) and subjected to chemiluminescence.  Band intensity was quantified by densitometry 
using NIH ImageJ and normalized to GAPDH loading controls. 
 
Immunocytochemistry 
C-kit
+
 cells cultured on Lab-Tek™ II 4-well chamber slides (Nunc) and treated with adenovirus 
(AdsiCON, AdsiNox2, and/or AdsiNox4) were fixed in 4% PFA for 25 minutes at room 
temperature (RT) and washed 3 times with DPBS (Gibco).  Cells were stored at 4 ºC in DPBS 
until immunocytochemistry was performed.   
 
For primary antibodies monoclonal mouse anti-α-SMA (1:15, Dako, M0851) 6 and monoclonal 
mouse anti-cTnT (1:150, Thermo Scientific, MS-295-P0) 
6
 the following protocol was followed.  
Cells were permeabilized for 15 minutes with .05% Triton-X (Fisher Scientific) in TBS (Bio-
Rad) and blocked for 1.5 hours with Mouse Ig Blocking Reagent (M.O.M. Immunodetection Kit, 
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Vector Laboratories) followed by 10% normal donkey serum (Millipore) for 30 minutes at RT.  
After a quick wash with TBS, primary antibodies were diluted in M.O.M. Diluent (M.O.M. 
Immunodetection Kit, Vector Laboratories) and applied overnight at 4 ºC in a humidified 
chamber.  Cells were then washed 3 times with TBS and incubated with AlexaFluor 594 donkey 
anti-mouse IgG (1:200, Invitrogen) diluted in M.O.M. Diluent for 1 hour at RT.  After secondary 
incubation, cells were washed 4 times with TBS.  Stained cells were then mounted with 
Vectashield mounting media with DAPI for fluorescence (Vector) and quantified.  The percent 
of positive cells in each condition was determined and expressed fold AdsiCON.  A “no primary 
antibody” control was utilized to determine specificity.  Images were obtained using a Retiga 
1300i camera (QImaging) connected to a Nikon Eclipse 80i microscope.  Three biological 
samples were evaluated.   
 
For primary antibody polyclonal rabbit anti-Ki67 (1:100, Abcam, ab15580) the following 
protocol was followed.  Cells were permeabilized for 15 minutes with .2% Triton-X in TBS and 
washed 2 times for 2 minutes each with TBS.  Cells were then blocked in 10% normal donkey 
serum for 1 hour and 15 minutes at RT.  After a quick wash, the primary antibody was diluted in 
.05% Triton-X/1% normal donkey serum/1% normal mouse serum (Jackson ImmunoResearch 
Laboratories) in TBS for 1 hour at RT.  Cells were then washed 4 times with TBS and incubated 
with AlexaFluor 594 donkey anti-rabbit IgG (1:100, Invitrogen) diluted in .05% Triton-X in TBS 
for 45 minutes at RT.  After secondary incubation, cells were washed 4 times with TBS.  Stained 
cells were then mounted with Vectashield mounting media with DAPI for fluorescence (Vector) 
and imaged using a Retiga 1300i camera (QImaging) connected to a Nikon Eclipse 80i 
microscope.  The percent of positive cells in each condition was determined.  A “no primary 
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antibody” control was utilized to determine specificity.  Three biological samples were 
evaluated.  
  
RT
2
 Profiler PCR Arrays 
Directly following FACS, RNA was isolated from freshly isolated c-kit
+
 cells and control 
cardiomyocytes using an optimized version of the TRIzol (Invitrogen) protocol to increase 
precipitation time in isopropanol.  RNA was pooled from 2 independent cell sorts to accumulate 
1000 ng total RNA and assigned RIN values by an Agilent 2100 bioanalyzer.  cDNA first was 
synthesized using the RT
2
 First Strand Kit and then added to the RT
2
qPCR Master Mix 
according to manufacturer’s instructions (Qiagen-SABiosciences).  The mixture was aliquoted 
across the PCR Array plates and thermal cycling was performed (see qPCR Section).  Data was 
analyzed using the RT² Profiler PCR Array Data Analysis Template available on the 
manufacturer’s website. 
 
Statistical Analysis 
Results are expressed as mean ± SEM.  Data were analyzed by Student’s t test for comparisons 
between two groups, or ANOVA followed by the Tukey post-test for multiple comparisons.  
Statistical analyses were performed using Prism (GraphPad Software, Inc.). 
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RESULTS 
 
C-kit
+
 CPCs Exhibit Reduced ROS Levels In Vitro and In Vivo 
Emerging data indicate that some precursor cell types reside in relatively low ROS niches to 
maintain their stemness 
34-36
.  To determine the intracellular ROS profile of c-kit
+
 CPCs in vitro 
and in vivo, I utilized DHE microfluorography.  As shown in representative images (Figures 
3.2A-B) and in summary (Figure 3.2C), there was a significant decrease in DHE fluorescence 
intensity in early postnatal c-kit
+
 CPCs compared to c-kit
-
 cells (2.15-fold, p<0.05).  To rule out 
the possibility that cell isolation and culturing conditions altered the physiological redox state of 
c-kit
+
 CPCs, I also utilized in vivo DHE microfluorography to measure ROS levels of c-kit
+
 
CPCs within the intact left ventricular myocardium of c-kit
BAC
-EGFP neonates.  Similar to my 
observations from the in vitro study, representative DHE microfluorography confocal images 
(Figures 3.2D-E) and summary data (Figure 3.2F) revealed a significant decrease in ROS levels 
in ventricular c-kit
+
 CPCs compared to neighboring c-kit
-
 cells (1.84-fold, p<0.05).  Taken 
together, these results demonstrate reduced ROS formation within c-kit
+
 CPCs. 
 
Nox2 is Selectively Downregulated in Freshly Isolated C-kit
+
 CPCs and is Upregulated Along 
with Nox4 Over the Course of Differentiation 
Given the importance of Nox enzymes in cardiac ROS generation and signaling 
10, 11
, I utilized 
qPCR to profile basal transcript levels of Nox1, 2, and 4, along with a subset of their subunits, in 
freshly isolated early postnatal c-kit
+
 and control cells.  As shown in Figure 3.3A, Nox1 and 
Nox4 were expressed at low but detectable levels, but showed no difference in expression 
between control cardiomyocytes and freshly isolated c-kit
+
 CPCs (1.45-fold and 1.52-fold, 
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Figure 3.2.  C-kit
+
 CPCs Exhibit Reduced ROS Levels In vitro and In vivo.  (A)  
Representative green fluorescent image of a c-kit
+
 cell (white arrow) and three c-kit
-
 cells 
(white inverted triangles) isolated from PN0-4 heterozygote c-kit
BAC
-EGFP pup hearts and 
cultured for 48 hours; scale bar = 20µm.  (B)  Red fluorescent image from same field 
demonstrating that the c-kit
+
 cell (white arrow) shows lower DHE fluorescence intensity than 
the c-kit
-
 cells (white inverted triangles); scale bar = 20µm.  (C) Summary of in vitro DHE 
fluorescence intensity in c-kit
-
 and c-kit
+
 cells (3 separate experiments).  (D)  Green 
fluorescent image of c-kit
+
 cells (white arrows) residing in the left ventricular myocardium of 
PN0 homozygote c-kit
BAC
-EGFP pup hearts.  (E)  Corresponding red fluorescent image from 
same field demonstrating that the c-kit
+
 cells (white arrows) show lower DHE fluorescence 
intensity than neighboring c-kit
-
 cells.  (H)  Summary of in vivo DHE fluorescence intensity 
in neighboring c-kit
-
 cells and c-kit
+
 cells (n=5 neonates).  Numbers of cells analyzed in each 
experiment are depicted on the bars; *p<0.05 vs. c-kit
+
 cells. 
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respectively, p>0.05).  Moreover, two subunits required for Nox1 activity, NoxA1 and NoxO1, 
displayed no difference in expression between the groups (1.26-fold and 1.33-fold, respectively, 
p>0.05; Figure 3.3B).  Similarly, p22
phox
, a subunit utilized by all three of the cardiac Nox 
enzymes and the only subunit necessary for Nox4 activity 
11
, was unchanged between c-kit
+
 and 
control cells (1.06-fold, p>0.05; Figure 3.3B).  Interestingly, Nox2 was expressed at markedly 
higher levels than Nox1 and Nox4 in control cardiomyocytes, consistent with previous reports 
for primary rat neonatal cardiomyocytes 
32
, however freshly isolated c-kit
+
 CPCs showed a 
dramatic reduction in basal Nox2 expression compared to control cardiomyocytes (12.0-fold, 
p<0.05; Figure 3.3A).  Expression of p67
phox
, a critical player in Nox2 activity 
11
, also was 
reduced significantly in freshly isolated c-kit
+
 CPCs compared to controls (2.71-fold, p<0.05; 
Figure 3.3B).  Together, these data reveal marked downregulation of the potent ROS generator 
Nox2 and its critical subunit p67
phox 
in freshly isolated c-kit
+
 CPCs, which may contribute to the 
low ROS levels observed in these cells (see Figure 3.2). 
 
Having identified a unique basal Nox expression profile in freshly isolated c-kit
+
 CPCs, next I 
examined whether Nox enzyme expression was induced upon differentiation as has been 
reported for ESCs 
20, 21, 37
 and adult cardiac stem cells 
22
.  C-kit
+
 CPCs were cultured for 3, 9, or 
14 days and Nox enzyme expression was profiled by qPCR as above.  As seen in Figure 3.3C, 
Nox1 transcript levels remained low, but detectable, and did not change significantly throughout 
the differentiation time-course.  Similar to basal expression data, Nox2 transcript levels were low 
and remained so at Days 3 and 9, however by Day 14 there was a marked upregulation of this 
Nox homologue (8.96-fold vs. Day 3 and 12.18-fold vs. Day 9, p<0.05).  Nox4 exhibited a 
gradual increase in expression over time, and by Day 14 (5.21-fold vs. Day 3, p<0.05) was 
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Figure 3.3.  Nox2 is Selectively Downregulated in Freshly Isolated C-kit
+
 CPCs and is 
Upregulated Along with Nox4 Over the Course of Differentiation.  (A)  Summary of basal 
Nox homologue and (B) a subgroup of Nox subunit mRNA levels analyzed by qPCR in 
control cardiomyocytes and freshly isolated c-kit
+
 cells.  n=6/group for Nox homologues, 
n=3/group for Nox subunits; *p<0.05 vs. control cardiomyocytes; †p<0.05 vs. Nox1 and 
Nox4.  (C)  Transcript levels of Nox1, 2, and 4 in c-kit
+
 cells cultured for 3, 9, and 14 days.  
n=4/group; * p<0.05 vs. Day 3, † p<0.05 vs. Day 9.  Gene expression was normalized to β-
actin.  
 114 
 
  
  
 115 
 
similar to Nox2 expression.  Together, these findings demonstrate that Nox2 and Nox4 are 
upregulated in a time-specific manner over the course of c-kit
+
 CPC differentiation, suggesting 
they may be involved in ROS-mediated cardiac lineage commitment.  
 
Targeted Silencing of Nox2 and Nox4 Alters C-kit
+
 Precursor and Lineage Commitment 
Status  
To determine if Nox2 and Nox4 are functionally linked to c-kit
+
 precursor cell status and/or cardiac 
cell differentiation in vitro, I utilized adenoviruses encoding U6 promoter-driven siRNAs targeted 
to Nox2 (AdsiNox2) or Nox4 (AdsiNox4) previously established in our laboratory 
30, 32, 33
.  
Importantly, our laboratory has demonstrated that these viruses efficiently and selectively silence 
Nox2 and Nox4, respectively, in cultured cardiomyocytes and in vivo 
30, 32, 33
 as well as in 
neonatal c-kit
+
 CPCs (Figures 3.1A-B).  C-kit
+
 CPCs isolated from early postnatal c-kit
BAC
-
EGFP hearts were infected with one or both of these adenoviruses or a control virus (AdsiCON) 
and expression of several cardiac precursor (c-kit and Flk-1) 
5-7
 and differentiation genes (α-
Smooth Muscle Actin, α-SMA; cardiac Troponin T, cTnT; endothelial Von Willebrand Factor, 
vWF) 
6, 7
 were analyzed by qPCR.   
 
As shown in Figure 3.4A, c-kit
+
 CPCs infected with AdsiNox2 exhibited a significant increase in 
precursor genes c-kit and Flk-1 (10.27-fold and 14.27-fold, respectively, p<0.05) compared to 
cells infected with a control siRNA (AdsiCON).  This was accompanied by a marked 
downregulation of α-SMA (4.02-fold, p<0.05), but no effect on cTnT or vWF transcript levels 
(Figure 3.4D).  Interestingly, cells infected with AdsiNox4 also demonstrated a significant 
increase in one of the stemness markers (Flk-1, 12.12-fold, p<0.05), and in these cells there was 
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Figure 3.4.  Targeted Silencing of Nox2 and Nox4 Increases Expression of Cardiac 
Precursor Genes and Decreases Expression of Specific Differentiation Genes.  (A-C) 
Transcript levels for stemness genes c-kit and Flk-1 and (D-F) differentiation genes α-SMA, 
cTnT, and vWF analyzed by qPCR in c-kit
+
 cells isolated from PN0-4 heterozygote c-kit
BAC
-
EGFP pup hearts and infected with AdsiCON, AdsiNox2, AdsiNox4, or AdsiNox2/4.  qPCR 
was performed 7 days post-infection.  n=4-5/group; *p<0.05 vs. AdsiCON.  Gene expression 
was normalized to β-actin.  
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a corresponding and selective decrease in cTnT (11.48-fold, p<0.05) with no changes observed 
in the other differentiation markers compared to control treatment (Figures 3.4B and 3.4E).  
Finally, co-infection of c-kit
+
 CPCs with AdsiNox2 and AdsiNox4 triggered a marked increase 
in both of the precursor genes c-kit and Flk-1 (9.65-fold and 43.63-fold, respectively, p<0.05) 
compared to AdsiCON (Figure 3.4C).  This was accompanied by marked decreases in both α-
SMA (14.20-fold, p<0.05) and cTnT (18.79-fold, p<0.05) transcript levels, but still no effect on 
the endothelial marker vWF (Figure 3.4F).  Interestingly, another gene utilized for the induction 
of pluripotent stem cells, Klf4 
38
, was found to be expressed at detectable levels in c-kit
+
 cells 
treated with control virus (AdsiCON), but was unaltered upon knockdown of Nox2 and/or Nox4 
(data not shown).   
 
Because mRNA levels of vWF were low and unaltered in each of the experiments, I also 
investigated expression of VEGF-A, a growth factor critical for endothelial cell differentiation 
and proliferation 
39, 40
.  I found that VEGF-A was expressed at detectable levels in c-kit
+
 CPCs, 
however, no changes in transcript levels were observed upon silencing of Nox2 and/or Nox4 
(Figure 3.5A).  In addition, I sought to verify that viral silencing of the Nox enzymes, either 
separately or in combination, did not alter cell proliferation when compared to cells transduced 
with the control vector.  As seen in Figures 3.6A-C, there were no differences in expression of 
the cell proliferation marker Ki67 in any of the virus treatment groups compared to AdsiCON-
treated c-kit
+
 CPCs.       
 
To further verify these findings and validate the mRNA data observed with Nox isozyme 
silencing, I next performed a series of western immunoblot and immunocytochemistry 
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Figure 3.5.  Targeted Silencing of Nox2 and Nox4 does not Alter VEGF-A Expression.  
(A) VEGF-A transcript levels analyzed by qPCR in c-kit
+
 cells isolated from PN0-4 
heterozygote c-kit
BAC
-EGFP pup hearts and infected with AdsiCON, AdsiNox2, AdsiNox4, 
or AdsiNox2/4 for 7 days.  n=3-5/group.  No significant differences were observed between 
the groups; p>0.05 vs. AdsiCON.  Gene expression was normalized to β-actin.  
 120 
 
 
  
Figure 3.6.  Targeted Silencing of Nox2 and Nox4 does not Alter Cell Proliferation. 
Representative images of Ki67 immunocytochemistry in DAPI-stained c-kit
+
 cells isolated 
from PN0-4 heterozygote c-kit
BAC
-EGFP pup hearts and treated with (A) AdsiCON and (B) 
AdsiNox2/4 for 7 days; scale bar = 10µm.  (C) Summary of percent of total cells positive for 
Ki67 at Day 7 following viral transduction.  No significant differences were observed 
between the groups.  3 independent experiments were analyzed comprising ≥200 
cells/condition; p>0.05 vs. AdsiCON. 
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 experiments.  As shown in Figure 3.7A, I observed significant increases in total c-kit protein 
after either AdsiNox2 (2.54-fold, p=0.05) and AdsiNox4 (2.48-fold, p<0.05) alone or in 
combination (4.31-fold, p=0.05) compared to AdsiCON.  I also examined the percent of cells 
expressing either α-SMA or cTnT using immunocytochemistry.  Importantly, the proportions of 
control cells expressing differentiation markers α-SMA and cTnT (Figures 3.7D-3.7E) were 
similar to our laboratory’s previous report 6.  As shown in representative images (Figures 3.7B-
C) and summary graphs (Figures 3.7D-E), and in line with my mRNA data, significant 
reductions in the percent of α-SMA-expressing cells after treatment with AdsiNox2 (6.64-fold, 
p<0.05) or AdsiNox2/4 (6.37-fold, p<0.05) and cTnT-expressing cells after treatment with 
AdsiNox4 (4.02-fold, p<0.05) or AdsiNox2/4 (104.96-fold, p<0.05) were observed.  Knockdown 
of Nox2 also led to a reduction in the percent of cTnT-positive cells (7.95-fold, p<0.05), even 
though the decrease in cTnT transcript level was not different from control (Figure 3.4D).  
Collectively, these results demonstrate that low levels of Nox2 and Nox4 are critical for the 
maintenance of precursor status in these c-kit
+
 CPCs, and that increasing levels of Nox2 and 
Nox4 are important for expression of smooth muscle and cardiac cell markers. 
 
Targeted Silencing of Nox2 and Nox4 Alters Expression of Transcription Factors and 
Cytokines 
In order to begin to tease apart the mechanisms by which Nox isoforms act during c-kit
+
 CPC 
specification, I utilized qPCR to measure the expression levels of two transcription factors, 
Gata6 and Gata4, and the cytokine, TGF-β1, each known to play important roles in cardiac 
lineage commitment 
41
.  As shown in Figure 3.8A, viral silencing of Nox2 reduced the 
expression of the smooth muscle-specific transcription factor Gata6 (2.51-fold, p<0.05) and 
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Figure 3.7.  Targeted Silencing of Nox2 and Nox4 Alters Population of Lineage 
Committed Cells.  (A) Representative immunoblot (left) and summary (right) of 
quantification of c-kit protein in cell lysates from c-kit
+
 cells isolated from PN0-4 
heterozygote c-kit
BAC
-EGFP pup hearts and infected with AdsiCON, AdsiNox2, AdsiNox4, 
or AdsiNox2/4 for 7 days.  n=3; *p<0.05 vs. AdsiCON, †p=.05 vs. AdsiCON.  
Immunocytochemistry for (B) α-SMA and (C) cTnT in virally transduced c-kit+ cells; scale 
bar = 10µm.  Summary of percent of total cells positive for (D) α-SMA and (E) cTnT 7 days 
following viral transduction.  4 independent experiments were analyzed comprising ≥550 
cells/condition; *p<0.05 vs. AdsiCON. 
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Figure 3.8.  Targeted Silencing of Nox2 and Nox4 Alters Expression of Transcription 
Factors and Cytokines.  (A-C) Gata6, Gata4, and TGF-β transcript levels analyzed by qPCR 
in c-kit
+
 cells isolated from PN0-4 heterozygote c-kit
BAC
-EGFP pup hearts and infected with 
AdsiCON, AdsiNox2, AdsiNox4, or AdsiNox2/4 for 7 days.  n=3-6/group; *p<0.05 vs. 
AdsiCON.  Gene expression was normalized to β-actin. 
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 significantly increased expression of TGF-β1 (3.35-fold, p<0.05), which is a critical modulator 
of ESC-mediated smooth muscle generation 
42
.  AdsiNox4 significantly increased expression of 
the early cardiac transcription factor Gata4 (2.48-fold, p<0.05) and TGF-β1 (2.43-fold, p<0.05), 
but had no effect on Gata6 expression (Figure 3.8B).  In combination, knockdown of Nox2 and 
Nox4 led to a significant reduction in Gata6 mRNA expression (2.58-fold, p<0.05) along with a 
significant increase in both Gata4 (1.82-fold, p<0.05) and TGF-β1 (4.98-fold, p<0.05) mRNA 
levels (Figure 3.8C).  Thus, it appears that Nox2- and Nox4-derived ROS may target the early 
transcription pathways necessary for mesodermal differentiation. 
 
C-kit
+
 CPCs Exhibit Enhanced Antioxidant Capacity at the mRNA Level 
Thus far, I have focused on pro-oxidant generators and their influence over c-kit
+
 CPC function; 
however, I speculate that overall redox balance is an important modulator of c-kit
+
 CPC state and 
I recognize that a variety of antioxidants likely are involved in the pathways mediating CPC self-
renewal and differentiation.  Therefore, I turned to the RT
2
 Profiler PCR Array system to 
simultaneously monitor the mRNA expression levels of 84 different genes involved in Mouse 
Oxidative Stress and Antioxidant Defense systems in a population of freshly isolated c-kit
+
 
CPCs.  Utilizing qPCR, I found that 23 redox genes were upregulated and 4 genes were 
downregulated in freshly isolated c-kit
+
 cells compared to control cardiomyocytes (Figure 3.9A 
and Tables 3.2 and 3.3).  Fold changes were considered significant at a ≥2-fold change in either 
direction (p<0.05).  Of these 23 genes, many represented entire families of redox-related 
molecules.  For example, upregulated genes included two of the three superoxide dismutase 
isoforms (Sod1, Sod2) and four members of the peroxiredoxin family (Prdx2, Prdx3, Prdx5, 
Prdx6), all of which are involved in ROS scavenging.  The four downregulated genes included 
the third member of the Sod family (Sod3), apolipoprotein E, cytoglobin, as well as previously 
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Figure 3.9.  C-kit
+
 CPCs Exhibit Enhanced Antioxidant Capacity at the mRNA Level. 
(A) Summary of transcript levels of 84 redox genes analyzed by RT
2
Profiler PCR Array in c-
kit
+
 cells and control cardiomyocytes isolated from PN0-4 heterozygote c-kit
BAC
-EGFP and 
wildtype littermate pup hearts, respectively.  Fold changes were considered significant at ≥2-
fold change in either direction (solid lines).  n=3; p<0.05.  (B)  Summary of a subset of 
upregulated and downregulated genes analyzed by qPCR in c-kit
+
 cells and control 
cardiomyocytes expressed fold control cardiomyocytes and compared to the Array data-set.  
n=3; p>0.05. Gene expression was normalized to β-actin.  
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Table 3.2.  23 Upregulated Redox Genes and their Functions. 
 
  
Upregulated       
Gene 
Fold Change 
(≥2) 
P value 
(<.05) Gene Function 
Mb  12.09 0.0188 Globin, storage/movement of O2 in muscle 
Xirp1  10.8 0.0028 Stabilizes actin filaments 
Tmod1  10.56 0.0029 Blocks depolarization of actin filaments 
Prdx3  5.42 0.041 Reduces H2O2 and alkyl hydroperoxides in mitochondria 
Nqo1  5.13 0.0215 Quinone reductase, cellular detoxification 
Slc41a3  4.45 0.0108 Magnesium transporter 
Sod2  4.11 0.0077 Dismutates superoxide in mitochondria 
Gstk1  3.8 0.0211 Glutathione transferase, cellular detoxification 
Gpx4  3.78 0.0153 Catalyzes reduction of H2O2 
Prdx2  3.67 0.0215 Reduces H2O2 and alkyl hydroperoxides in cytosol 
Txnrd2  3.53 0.0115 Reduces thioredoxin 
Slc38a1  3.47 0.0007 Amino acid transporter 
Prdx5  3.38 0.0028 
Reduces H
2
O
2
 and alkyl hydroperoxides in 
mitochondria/peroxisomes 
Prdx6-rs1  3.27 0.0014 Peroxiredoxin 6 related sequence-1 
Prdx6  3.17 0.0042 Reduces H2O2 and alkyl hydroperoxides in cytosol 
Psmb5  3.14 0.0163 Proteasome subunit 
Txnip  3.02 0.0488 Inhibits thioredoxin activity 
Sod1  2.94 0.0486 Dismutates superoxide in cytoplasmic compartment 
Park7 2.63 0.0043 Member of peptidase C56 family, sensor of oxidative stress 
Nudt15 2.6 0.0205 Helps prevent incorporation of 8-oxo-dGTP into DNA 
Catalase 2.22 0.0312 Decomposes H2O2 
Dnm2 2.17 0.015 GTP-binding protein, endocytosis 
Ptgs1 2.13 0.0154 Prostaglandin synthesis, cell proliferation 
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Table 3.3.  4 Downregulated Redox Genes and their Functions. 
 
  
Downregulated       
Gene Fold Change (≥2) P value (<.05) Gene Function 
Cygb  0.12 0.0002 O2 storage/transfer 
Sod3  0.25 0.0188 Dismutates superoxide in extracellular compartment 
Ncf2 (p67phox) 0.37 0.0196 Subunit of NADPH oxidase complex in neutrophils 
Apoe 0.4 0.0062 Lipoprotein metabolism 
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identified pro-oxidant, p67
phox
.  RT
2
Profiler PCR Array results were confirmed using 
independently designed qPCR primers for select target genes run on 3 distinct samples, and close 
alignment was found (Figure 3.9B).  These data reveal an interesting genetic redox profile in 
freshly isolated c-kit
+
 CPCs which introduces new molecules that likely contribute to 
maintenance of a low ROS state and preservation of a stemness phenotype. 
 
  
 132 
 
DISCUSSION 
 
With cell-based therapies emerging as potential strategies for a variety of disease states including 
heart failure 
41
, it is increasingly important to understand the mechanisms underlying precursor 
cell self-renewal and differentiation.  Redox signaling is recognized to play key roles both in 
maintaining stemness and in mediating lineage commitment in multiple precursor cell types 
8, 9
.  
However, currently little is known about the redox status of c-kit
+
 CPCs and the interplay 
between ROS and CPC differentiation. Here I report that early postnatal c-kit
+
 CPCs exhibit 
reduced ROS levels under basal conditions, and that Nox2 and Nox4 modulate the balance 
between c-kit
+ 
cell precursor and differentiation status in part by altering the expression of 
transcription factors Gata6 and Gata4 and the cytokine TGF-β1.         
 
Several precursor cell types, including endothelial progenitor cells (EPCs) and hematopoietic 
stem cells have now been shown to exist in a ROS-protected state 
34-36
.  It is postulated that this 
may be necessary for progenitor cell survival by shielding them from DNA damage, and also to 
promote progenitor status by limiting their exposure to molecules that trigger differentiation 
34-36, 
43, 44
.  Using DHE as a ROS indicator in freshly isolated c-kit
+
 CPCs in vitro and in the intact 
myocardium of early postnatal c-kit
BAC
-EGFP mice, this is the first report to demonstrate that 
early postnatal c-kit
+
 CPCs also exhibit reduced ROS levels.  While I am aware that DHE 
fluorescence intensity is a semi-quantitative measurement of ROS, I believe that, similar to these 
other cell types, my findings reflect the fact that c-kit
+
 CPCs reside within well-protected niche 
environments 
35, 36
. 
 
 133 
 
After demonstrating a decrease in ROS production in c-kit
+
 CPCs, next I turned to analyzing 
Nox1, Nox2, and Nox4 since they are the main ROS generators in cardiovascular tissues and are 
known to be involved in cardiac signaling and differentiation 
10, 11
.  Nox1, which has limited 
expression in the mature heart 
10, 11
, was expressed at low basal levels both in early postnatal c-
kit
+ 
CPCs and control cardiomyocytes, and, unlike the other two homologues, showed no 
induction upon c-kit
+
 CPC differentiation.  In addition, the two required subunits for Nox1 
activity, NoxA1 and NoxO1, also were not differentially expressed in c-kit
+
 CPCs.  Therefore, 
Nox1 likely plays a very limited role in c-kit
+
 cell precursor status or lineage commitment.  On 
the other hand, Nox2 and its critical functional subunit, p67
phox
, were significantly 
downregulated in early postnatal c-kit
+
 CPCs compared to control cells.  Interestingly, this was 
not the case for Nox4, which leads me to speculate that the low ROS state of early postnatal c-
kit
+
 CPCs is due at least in part to selective downregulation of Nox2 expression and function in 
these cells.  However, like in other precursor cell populations 
34
, the results of the RT
2
Profiler 
PCR arrays suggest that increased expression of antioxidant enzymes such as Sod, Prdx, Gpx, 
and catalase also contribute to the low ROS state of c-kit
+
 CPCs and I am currently investigating 
the influence of these additional redox targets on c-kit
+
 cell precursor status and differentiation.     
Both Nox2 and Nox4 exhibited increased expression over the course of c-kit
+
 cell differentiation, 
with Nox4 showing upregulation somewhat earlier than Nox2.  This is consistent with evidence 
that both of these homologues are expressed in multiple developing and mature cardiac cell types 
10, 11, 17, 20, 21, 37
.  Previously, our laboratory reported that c-kit
+
 cells differentiate into all three 
lineages of the heart in vitro 
6
, so to determine if Nox2 and/or Nox4 are functionally linked to c-
kit
+
 CPC differentiation, I went on to utilize gene silencing viruses targeted selectively to each of 
these two homologues 
30, 32, 33
.  Upon knockdown of Nox2, there was a significant increase in 
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both the CPC marker c-kit and the early mesodermal cell marker Flk-1, concomitant with a 
decrease in expression of α-SMA at the mRNA and protein levels.  Although it has been reported 
previously that Nox2 plays a key role in skeletal muscle differentiation 
45
 and in 
remodeling/revascularization after ischemic injury in other systems 
14, 15
, this is the first report 
that Nox2 is critical for the differentiation of CPCs along the smooth muscle lineage.  In line 
with previous reports that Gata6 expression follows that of α-SMA 46, I also observed a 
significant downregulation of Gata6 mRNA in AdsiNox2-transduced c-kit
+
 CPCs, and this was 
not further altered by the addition of AdsiNox4.  This was accompanied by significant 
upregulation of TGF-β1, which is consistent with reports that Gata6 is critical for the 
maintenance of a differentiated phenotype in VSMCs and is a known to be a suppressor of TGF-
β147, 48.  Because these transcription factors and this cytokine have broad cellular implications, it 
is not surprising that downregulation of Nox2 also led to a significant reduction in the number of 
cTnT-expressing cells, even though this was not significant at the transcript level.  Together with 
a recent report that Nox2 contributes to cardiomyogenesis by ESCs 
21
, these data suggest that 
Nox2- derived ROS plays a critical role in the smooth muscle and perhaps cardiac commitment 
of c-kit
+
 CPCs. 
 
A role for Nox4 in ESC-mediated cardiomyogenesis recently has emerged 
20, 37
, and my studies 
suggest a similar mechanism at play in the differentiation of c-kit
+
 CPCs along the 
cardiomyocyte lineage.  Selective knockdown of Nox4 with AdsiNox4 reduced expression of 
cTnT mRNA as well as the percent of cells expressing cTnT protein.  As with AdsiNox2 
treatment, this was accompanied by increased expression of stemness markers c-kit and Flk-1.  
Interestingly, although previous reports also link Nox4 to smooth muscle cell differentiation 
17
, 
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my data do not support a similar role for Nox4 since AdsiNox4 did not significantly alter α-SMA 
transcript levels or the percent of α-SMA-positive cells.  Furthermore, AdsiNox4 did not alter 
Gata6 expression, whereas it did alter expression of early cardiac transcription factor Gata4.  As 
Gata4 is regulated through both ROS-dependent and ROS-independent pathways, I hypothesize 
that the increase in Gata4 observed after silencing Nox4 is a result of a ROS-independent and 
antioxidant-sensitive mechanism 
49
.  This is further supported by the fact that Gata4 is a retinoic-
acid inducible transcription factor in the heart 
50
.  In addition, treatment with AdsiNox4 
significantly increased transcript expression of TGF-β1, a finding consistent with evidence that 
signaling through TGF-β1 is critical for cardiomyogenesis 51.  Further studies will be required to 
elucidate these mechanisms.    
 
In line with our laboratory’s earlier report that approximately 39% of c-kit+ CPCs analyzed 24 
hours post-FACS express α-SMA, 30% express cTnT, and a negligible number express 
endothelial markers PECAM1 or vWF 
6
, I noted very low but detectable levels of vWF in all 
conditions, and failed to observe differential effects of AdsiNox2 and/or AdsiNox4 on 
endothelial cell differentiation.  This was verified further using VEGF-A, a growth factor critical 
for endothelial cell differentiation and proliferation 
39, 40
.  It should be noted, however, that I 
cannot rule out the possibility that specific media conditions and growth factors vital for 
endothelial cells to differentiate from c-kit
+
 CPCs were lacking in my protocol and this may have 
contributed to my findings 
6
.  While I believe it is unlikely that Nox2 or Nox4 play a prominent 
role in the differentiation of c-kit
+
 CPCs into mature endothelial cells, it remains to be elucidated 
whether overall redox state and/or Nox signaling via other Nox homologues are critical for the 
differentiation of c-kit
+
 CPCs along the endothelial cell lineage in optimized media conditions. 
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Although it is clear that ROS derived from the different Nox isoforms feed into divergent 
signaling cascades and lead to specific cellular outcomes 
11
, my data suggest that there also may 
be convergent signaling pathways for Nox-derived ROS in c-kit
+
 CPCs.  For example, when 
AdsiNox2 and AdsiNox4 were used concomitantly, I observed a significant and even more 
robust upregulation of cardiovascular precursor marker Flk-1 than that observed after the 
downregulation of either Nox isoform alone.  Interestingly, Flk-1 also has been reported as a 
marker of EPCs 
52
 and vascular stem cells 
53
.  Because I did not observe an increase in 
endothelial cell markers after downregulation of Nox2 and Nox4, I do not believe that this 
increase in Flk-1 is indicative of a shift to an endothelial cell fate, but instead I hypothesize that 
it is a reversal to either a multipotent cardiovascular or a more restricted vascular precursor cell 
state.  The idea of convergent signaling pathways for Nox-derived ROS also was observed for 
TGF-β1 mRNA, where a more robust increase was seen after concurrent treatment with 
AdsiNox2 and AdsiNox4.  The augmentation in induction observed here may reflect an attempt 
to overcompensate for the drastic loss of Nox signaling as TGF-β1 is a known agonist of Nox 
activity.     
 
In conclusion, my study reveals two novel redox targets, Nox2 and Nox4, which are involved in 
the balance between neonatal c-kit
+ 
cell precursor and differentiation status.  Utilizing 
microfluorography to measure ROS, along with genetic tools to profile and manipulate the redox 
status of early postnatal c-kit
+
 CPCs, my results demonstrate that c-kit
+
 CPCs exist in a low ROS 
state and that Nox2 and Nox4 are functionally linked to their differentiation into smooth muscle 
and cardiac cell lineages.  The downstream pathways modulated by Nox-derived ROS 
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production in CPCs also will require further study, but likely involve redox sensitive signaling 
pathways such as RAS, JNK, ERK1/2, p38MAPK, and PI3K 
11
.   Here I focused on pro-oxidant 
Nox isozymes, however, through the RT
2
Profiler PCR Arrays, I am cognizant that additional 
sources of ROS, most notably the mitochondria, as well as overall redox balance are likely 
important and that a variety of additional pro-oxidant and/or antioxidant molecules may be 
involved in the pathways mediating c-kit
+
 CPC self-renewal and differentiation.  Although 
uncovering the specific redox pathways and mechanisms that drive these outcomes will require 
additional investigation, I believe that this study highlights several target genes which may be 
utilized in directed differentiation for cell-based therapies of the heart. 
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CHAPTER FOUR: DISCUSSION 
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4.1 Summary of Findings 
 
CHD is one of the leading causes of morbidity and mortality in the developed world, producing 
an enormous economic burden on society 1.  To date, this cost to society has been unmet by 
scientific discovery of a true cure.  Heart disease is quickly becoming an epidemic problem made 
worse by an aging population and the retirement of individuals from the “baby boomer” 
generation.  Due to a severe lack of hearts available for organ transplantation, the field of 
regenerative cardiology has emerged as a way to couple advances from multiple disciplines to 
promote the creation of functional replacement myocardium.  While the fundamental view of the 
heart as a post-mitotic organ has been at the crux of basic research and clinical practice for a 
majority of the last century, the past few decades have witnessed a paradigm shift to the belief 
that the heart has some regenerative capability. 
 
In addition to the very recent proof of myocyte turnover by two independent groups 2, 3, the work 
presented in this thesis, along with the work of others 4, 5, provides strong experimental evidence 
indicating the presence of resident CPCs in the myocardium.  As described in the introduction 
and subsequent chapters, CPCs are identified by several markers including c-kit, which marks a 
CPC population exhibiting the three qualities of stemness 4-6.  This population shows great 
promise for cell-based therapy as its counterpart population also has been identified in humans 
and shown to possess similar cardiogenic properties 7, 8.   
 
Despite the presence of resident CPCs in the heart, the response of the heart to ischemic injury is 
principally one of fibrosis and non-contractile scar formation 9.   Several reasons for this 
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phenomenon exist, including the belief that stem cell niches in the heart play an important role in 
maintaining homeostasis, but do not respond well to injury or aging 10, 11.  Therefore, evidence 
presented in this thesis suggests that exogenous expansion and genetic manipulation of CPCs is 
necessary to achieve substantial cardiac regeneration following infarct.   
 
With the field of regenerative cardiology in its infancy and the discovery of CPCs less than a 
decade old, I sought a better understanding of the neonatal c-kit
+
 CPC population.  I 
hypothesized that the study of c-kit
+
 CPCs would provide important information regarding their 
genetic status, mechanisms of differentiation and commitment, as well as their biological and 
therapeutic potential.  Disheartened by the marginal improvements observed in cardiac function 
following cell therapy in conjunction with several strategies to precondition or genetically 
modify cells, I recognized the serious dearth of information regarding the basic mechanisms that 
regulate CPC stemness and differentiation.  Therefore, the work presented in this thesis provides 
the following information to the scientific community:  (1) A reproducible and reliable method to 
identify, isolate, and culture neonatal c-kit
+
 CPCs, (2) The characterization of neonatal c-kit
+
 
CPCs in vitro and an analysis of their lineage plasticity and capacity for differentiation, and (3) 
An understanding of the redox biology of neonatal c-kit
+ 
CPCs, with an eye toward better stem 
cell-based therapies in the future.  A detailed summary of findings from each chapter is presented 
below. 
4.1.1 Chapter 2 
Prior to these studies of c-kit expression in the murine heart, minimal promoter and 
enhancer elements as well as knock-in strategies were used to mark c-kit expression in 
the hematopoietic system, germ cells, gut, and brain 12, 13.  While the results of these 
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studies showed partial concordance between reporter and endogenous c-kit expression, an 
incomplete understanding of the regulatory elements necessary for normal c-kit 
expression coupled with the dominant nature of the c-kit gene complicated downstream 
analyses.  In order to circumvent these problems, our laboratory chose to generate a BAC 
transgenic mouse in which EGFP expression was placed under control of the c-kit 
promoter.  BAC recombineering has many benefits over traditional transgenesis, 
including a large insert size which contains most, if not all, of the cis-regulatory elements 
necessary for gene expression as well as some resistance against positional effects which 
may cause ectopic or weak transgene expression 14.  In addition, BAC constructs typically 
integrate at low copy number, less than five copies, as opposed to concatemer repeats of 
up to several hundred copies 14, 15.   
 
For our studies, we utilized standard PCR to identify a founder line and critically 
compared reporter gene EGFP expression with endogenous c-kit expression using a 
CD117 antibody (Chapter 2: Figures 2.1-2.2).  In order to accurately determine transgene 
copy number, the number of integration sites, and whether or not the BAC integrated as 
an intact construct, however, we recognize that we would need to perform additional 
experiments including Southern blot assays.  As expected from a genetic strategy in 
which the endogenous locus is not altered, the c-kit
BAC
-EGFP line displays no apparent 
phenotype and transmits the transgene in a Mendelian ratio.  The generation of this 
transgenic line not only allowed us to identify our target neonatal c-kit
+
 CPC population 
for the studies presented in this thesis, but also serves as a tool for the scientific 
community in the study of a variety of cells and tissues in which c-kit is a valid marker. 
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After verifying co-localization of expression between EGFP and c-kit in several tissues 
known to express c-kit, we went on to determine c-kit expression in early embryonic and 
postnatal hearts.  We identified clusters of c-kit
+
 cells in several areas of the heart 
including the atrial and ventricular walls (Chapter 2: Figure 2.2).  These precursor cell 
niches have been observed previously and suggest that specific locations within the heart 
that are protected from hemodynamic load and wall stress are critical for maintaining 
stemness 11, 16.  Not surprisingly, it has been reported that electrical impulse and 
mechanical strain contribute to ESC-mediated cardiomyogenesis 17-19.  In addition, the 
location of CPC clusters within the left ventricle is thought to strategically position 
primitive cells in close proximity to the site of ischemic injury, allowing for a shorter 
migratory path to the border zone 11.  Similar to the findings of Gude, et al. 20, we noted a 
small population of c-kit
+
 cells within the neonatal myocardium that accounted for less 
than 1% of the total heart population and declined significantly by adulthood.   Therefore, 
we decided to focus our studies on the early neonatal heart. 
 
To isolate c-kit
+
 cells and determine their potential to differentiate into multiple cell 
lineages, we designed and optimized a dissociation protocol adapted from Worthington’s 
Neonatal Cardiomyocyte Isolation System and utilized FACS to capture cells based on 
their EGFP fluorescence 21.  This sorting method avoided problems associated with 
possible epitope destruction by enzymatic digestion which might limit the pool of cells 
recognized by the c-kit antibody.  At 24 hours post-FACS, we confirmed previous reports 
of the progressive nature of the c-kit
+
 CPC population 22, demonstrating a mixed 
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population of cells with a majority co-expressing precursor cell marker nestin 23, 24 and 
approximately one-third expressing either smooth or cardiac muscle specific markers 
(Chapter 2: Figure 2.3).  In addition to expression of nestin, co-expression of Flk-1 also 
was observed in the PN2 heart, further supporting a precursor cell state (Chapter 2: 
Figure 2.2) 25, 26.  Interestingly, we saw no evidence of Sca-1 expression in our 
population, indicating partial digestion of the Sca-1 epitope during enzymatic cell 
dissociation, a completely distinct precursor cell population, or, more likely, precise 
temporal and spatial regulation over precursor antigen expression.  Not surprisingly, we 
observed no overlap in our CPC population with Isl-1, a precursor cell marker which is 
thought to be restricted to embryonic development 27 although its stemness has been 
called into question in recent years 10, 28. 
 
Because there are few c-kit
+
 cells in the neonatal heart, and an even smaller population in 
the adult myocardium, next we attempted to expand the c-kit
+
 population in vitro as a 
way to assess its therapeutic potential.  In culture, we observed evidence of cell 
proliferation by PCNA staining as well as the presence of all three cardiac lineages 
(smooth muscle, cardiac, and endothelial) (Chapter 2: Figure 2.3).  In addition, we 
confirmed the stemness of a sub-population of our c-kit
+
 cells through single cell 
dilutions in clonal assays (Chapter 2: Figure 2.5).   With directed differentiation 
becoming a critical modulator of cardiac repair, we investigated the lineage plasticity of 
our c-kit
+
 population by varying media conditions to include growth factors and 
cytokines which are known to be involved in mesodermal differentiation (Chapter 2: 
Figure 2.5).  The number of cells expressing cardiac marker, cTnT, was increased 
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markedly by inclusion of bFGF and these conditions produced a population of 
spontaneously beating cells.  The functional relevance of these rhythmic action potentials 
was analyzed by standard patch clamp methods and revealed characteristics similar to 
those reported previously for ESC-derived cardiomyocytes 29-31, suggestive of an 
immature cardiac phenotype (Chapter 2: Figure 2.4).  Beltrami, et al. 4 observed a similar 
phenotype noting that in vitro differentiated c-kit
+
 cells were morphologically 
underdeveloped and lacked mature sarcomeric structures. 
 
Following myocardial injury, our studies demonstrate that endogenous c-kit
+
 cells 
contribute to revascularization and fibrosis within the border zone of the infarcted heart, 
but their presence declines drastically within a few weeks (Chapter 2: Figure 2.6).  As 
mentioned previously, it is not surprising that endogenous stem cell niches are not 
capable of widespread cardiac repair, especially since many of these precursor cells 
succumb to apoptosis and necrosis alongside their mature counterparts 10.  Therefore, we 
believe that exogenous expansion of the CPC pool followed by cell therapy is necessary 
to achieve significant cardiac regeneration and functional restoration after injury.  While 
it is still unclear whether or not a subset of the c-kit
+
 population retains its multipotency 
after long-term expansion and passage in culture, some studies suggest the use of mixed 
populations in cell therapy, such as those derived from cardiospheres, to generate better 
cardiac outcomes, as these populations contain precursor cells capable of differentiation 
in addition to the supporting cells necessary for their survival 32.  However, before we can 
truly understand the therapeutic potential of c-kit
+
 CPCs in myocardial repair, the 
mechanisms driving c-kit
+
 CPC self-renewal and differentiation need to be elucidated. 
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4.1.2 Chapter 3 
In order to begin tease apart the signaling pathways mediating c-kit
+
 CPC self-renewal 
and differentiation, I turned my attention to the influence of redox biology over precursor 
cell state.  In 2002, two independent laboratories reported a molecular profile of stem 
cells using microarray to compare gene expression among HSCs, NSCs, and ESCs 33, 34.  
In total, approximately 200 genes were shared among the three cell types including a vast 
array of genes involved in resistance to stress.  These genes included up-regulated DNA 
repair mechanisms, protein folding chaperones, ubiquitin pathways, and toxic stress 
response systems 34.  Several years later, it was reported that EPCs and HSCs exhibit 
increased antioxidant capacity and reduced ROS formation 35, 36.  These characteristics 
were predicted to confer progenitor status and self-renewal capacity with increases in 
ROS driving differentiation 37.  Therefore, my initial goal for these studies was to 
determine whether or not c-kit
+
 CPCs also exhibit a protected redox profile in their basal 
state. 
 
I began my studies by utilizing DHE microfluorography to measure intracellular ROS 
levels in cultured c-kit
+
 CPCs as well as c-kit
+
 CPCs within the intact left ventricular 
niche.  Through these studies, I confirmed a low ROS state for c-kit
+
 CPCs (Chapter 3: 
Figure 3.2).  Overall, it is believed that a more reduced state favors self-renewal, while a 
more oxidized state promotes differentiation 38-42.  Therefore, my next step was to 
investigate which genes might be responsible for the initial low ROS state of c-kit
+
 CPCs 
and the subsequent increase in ROS necessary for cardiogenic differentiation.  Here, I 
turned to the cardiac Nox enzymes (Nox1, 2, and 4) which are essential components of 
 155 
 
cardiac redox biology and generate ROS in a highly regulated manner 43-45.  Through 
qPCR, I found that Nox2 and its critical subunit, p67
phox
, were downregulated in c-kit
+
 
CPCs (Chapter 3: Figure 3.3).  This finding highlighted a potential mechanism by which 
c-kit
+ 
CPCs maintain a low ROS state.  Next, I examined whether or not Nox homologue 
expression increases over the course of c-kit
+
 CPC differentiation.  Utilizing the same 
media conditions optimized in the studies presented in Chapter 2, I demonstrated a 
significant upregulation of both Nox2 and Nox4 by Day 14 in culture (Chapter 3: Figure 
3.3).  Together, these studies suggest a role for Nox2 and Nox4 in ROS-mediated cardiac 
lineage commitment of c-kit
+
 CPCs.  
 
To further confirm a functional role for Nox2 and Nox4 in c-kit
+
 CPC differentiation, I 
utilized an adenovirus mediated knockdown strategy to silence the Nox isoforms at Day 7 
in culture.  This timepoint was chosen to effectively blunt the significant increase in Nox 
isoform expression observed by Day 14.  Through qPCR, I measured transcript levels for 
two stemness genes, c-kit and Flk-1, as well as the three cardiac lineage commitment 
genes, α-SMA, cTnT, and vWF, at Day 7 post-transduction.  I noticed significant 
upregulation of stemness genes, c-kit and Flk-1, following knockdown of Nox2, but only 
a significant increase in Flk-1 after silencing Nox4 (Chapter 3: Figure3.4).  Not 
surprisingly, I observed a significant upregulation of both c-kit and Flk-1 after 
concomitant application of AdsiNox2 and AdsiNox4 (Chapter 3: Figure 3.4).  These 
findings verified a critical role for Nox signaling in c-kit
+
 CPC differentiation.  The fact 
that I observed such a robust change in stemness transcript following knockdown of 
Nox2 and Nox4 despite the fact that I started with a very mixed population, as 
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highlighted in Chapter 2, suggests some level of plasticity within the population as well 
as a high sensitivity to redox state.  The induction of c-kit transcript after application of 
AdsiNox2 and AdsiNox2/4 viruses was confirmed at the protein level using western 
immunoblot (Chapter 3: Figure 3.7).  Interestingly, I also observed a significant increase 
in c-kit protein after knockdown of Nox4, even though the increase in transcript level did 
not reach statistical significance. 
 
In addition to changes in stemness genes, I observed a decrease in commitment to the 
smooth muscle and cardiac lineages in a Nox2- and Nox4-dependent manner, 
respectively (Chapter 3: Figure 3.4), with little change seen in the generation of mature 
endothelial cells (Chapter 3: Figures 3.4 and 3.5).  Although previous reports indicate a 
role for Nox2 in skeletal muscle differentiation 46 and in vascular recovery after arterial 
injury and hindlimb ischemia  47, 48, this is the first report that Nox2 enzymatic activity is 
critical for the differentiation of CPCs along the smooth muscle lineage.  A role for Nox4 
in ESC-mediated cardiomyogenesis 49-51, however, is well established, and my studies 
suggest a similar mechanism is at work in the cardiac differentiation of c-kit
+
 CPCs.  
Changes observed in lineage commitment were verified at the protein level using 
immunocytochemistry with similar results (Chapter 3: Figure 3.7).  Interestingly, I 
observed a greater change in the number of cells expressing cTnT protein after treatment 
with AdsiNox2 than the change observed at the transcript level, suggesting that Nox2 
signaling also might be important for cardiac differentiation.  A similar contribution of 
Nox2 during cardiomyogenesis by ESCs was reported recently 50.  
 
 157 
 
In order to understand the mechanisms by which Nox-derived ROS act, next I examined 
the expression of several transcription factors and cytokines known to play a role in CPC 
lineage specification (Chapter 3: Figure 3.8).  My results indicate an increased presence 
of a population of cells in a pre-committed state.  For example, following knockdown of 
Nox2 and Nox4, I noted significant upregulation of TGF-β1 which is a known mediator 
of smooth muscle and cardiac differentiation 52-55.  In addition, I noted dysregulation of 
Gata6 and Gata4 after knockdown of Nox2 and Nox4, respectively, both of which are 
transcription factors involved in mesodermal differentiation and expressed at various 
time-points over the course of CPC lineage determination 22.  The molecular pathways by 
which these transcription factors and cytokines act during CPC commitment, however, 
remain to be seen. 
 
Because I am aware that other redox molecules likely are involved in the pathways 
mediating c-kit
+
 CPC self-renewal and differentiation, I utilized RT
2
Profiler PCR Arrays 
to measure the mRNA expression levels of 84 different genes involved in Mouse 
Oxidative Stress and Antioxidant Defense systems (Chapter 3: Figure 3.9 and Tables 3.2 
and 3.3). To this end, a wide-array of ROS scavengers were found to be upregulated in c-
kit
+
 CPCs including catalase, glutathione peroxidase 4 (Gpx4), several members of the 
peroxiredoxin (Prdx) family, and two Sod isoforms.   Upregulated genes also included 
Park7, a sensor of oxidative stress, and Nqo1, a molecule involved in the detoxification 
of quinones.  Downregulated genes included the potent pro-oxidant p67
phox
, as described 
above, along with the third Sod isoform, Sod3.  I speculate that these additional targets 
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play important roles in the redox biology of c-kit
+
 CPCs and will provide novel targets 
for understanding the pathways mediating their directed differentiation. 
 
4.2 Significance of Research and Proposed Model  
 
Because the field of regenerative cardiology proved too eager to progress from the bench to the 
bedside in its support of clinical trials utilizing skeletal myoblasts as a therapeutic population 56, I 
took a step back and evaluated the fundamental properties and basic mechanisms underlying the 
CPC phenotype.  Building from the discovery of resident CPCs in the early 2000’s, I chose to 
study a sub-population of CPCs which are marked by c-kit and known to exhibit the three 
qualities of stemness 4.  I hypothesized that the isolation and characterization of this population 
not only would contribute to the basic understanding of c-kit
+
 CPC biology, but also prove 
therapeutically meaningful in the treatment of myocardial infarction.  While my experiments 
were in progress, c-kit
+
 CPCs also were identified in the human myocardium and shown to have 
cardiogenic potential 8, 57, 58.  With clinical biopsies and ex vivo CPC expansion foreseeable events 
in patient care, I believed that studying the intricate pathways mediating c-kit
+
 CPC survival, 
proliferation, and differentiation was critical for the future success of the field. 
 
In contribution to the field, my studies in collaboration with my co-authors generated a BAC 
transgenic mouse in which c-kit expression can be identified easily by EGFP fluorescence.  This 
mouse is listed with Mouse Genome Informatics (MGI) under reference number 3760303 and is 
a useful tool for the study of a variety of developmental pathways and other pathologies in which 
c-kit is a target.  In addition, my studies were the first to evaluate the redox status of neonatal c-
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kit
+
 CPCs and, in doing so; I identified a number of dysregulated redox targets that influence the 
capacity of c-kit
+
 CPCs to differentiate.  I also provide a novel method for maintaining the 
stemness of the c-kit
+
 CPC population in vitro by silencing Nox2- and Nox4-mediated signaling.  
I hypothesize that this genetically altered population will be more resilient when transplanted 
into the infarcted heart.   Overall, the work presented in this thesis provides value to the field of 
regenerative cardiology as well as to those researchers interested in the intersection between 
stem cell and redox biology.   
  
From the data generated in this thesis, I have developed a two part model.  Each part is discussed 
below in detail. 
4.2.1 Part I 
Here, I describe the identification of a CPC population in the early neonatal heart that co-
expresses c-kit and Flk-1 (Figure 4.1).  While this is a very heterogeneous population, I 
have shown in clonal single cell expansions that a single c-kit
+
 CPC is capable of 
generating the three lineages that specify the heart: smooth muscle, cardiac, and 
endothelial, as depicted by left to right progression of a c-kit
+
Flk-1
+
 CPC transitioning to 
the three mature cell types (smooth muscle cells [SMCs], cardiomyocytes [CMs], and 
endothelial cells [ECs]).  To identify committed cells, I utilized α-SMA as a marker of 
smooth muscle cells, cTnT as a marker of cardiac cells, and PECAM/vWF as markers of 
endothelial cells all of which are indicated in the figure within each cell type.  Emerging 
evidence suggests that redox mechanisms play important roles in maintaining stemness 
and in mediating the survival, proliferation, and differentiation of some precursor cell  
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Figure 4.1.  Redox Control over C-kit
+
 CPC Status and Differentiation (Part I). 
C-kit
+
Flk-1
+
 CPCs exhibit an increased antioxidant capacity and a decreased pro-oxidant 
capacity.  This protected redox state is thought to contribute to stemness.  Over the course of 
differentiation, a tip in redox balance occurs and results in increased ROS production.  This 
phenomenon is mediated, in part, by the upregulation of Nox2 and Nox4.  Downregulated 
antioxidants have yet to be established.  The increase in ROS generation is necessary for the 
differentiation of c-kit
+
Flk-1
+
 CPCs into smooth and cardiac muscle, and, likely, endothelial 
cells.  Legend: ?? = unknown genes; Thin black arrow = progression to mature cell types; 
Dotted black arrow = possible contribution to mature cell type.  Abbreviations: CPC- Cardiac 
Precursor Cell, ROS- Reactive Oxygen Species, SMC- Smooth Muscle Cell, CM- 
Cardiomyocyte, EC- Endothelial Cell 
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types 38-42.  To this end, I found that our c-kit
+
Flk-1
+
 CPC population resides in a low 
ROS niche in vivo and, shortly following isolation, in vitro.  I identified a number of 
targets through qPCR and RT
2
Profiler PCR Arrays which contribute to this protected 
redox state including the upregulation of several antioxidants, a number of which are 
identified in the diagram (Figure 4.1), and the downregulation of a potent superoxide 
generator, Nox2, and its critical subunit, p67
phox
.  Increasing levels of ROS, shown in the 
figure by a swelling of the orange ROS banner, and subsequent redox signaling are 
thought to drive precursor cell differentiation.  Here, I illustrate the upregulation of two 
pro-oxidants, Nox2 and Nox4, over the course of c-kit
+
 CPC differentiation.  However, I 
am aware that a tip in redox balance also might include a decrease in the presence of 
antioxidants and/or dysregulation of additional pro-oxidants not examined in my assays, 
the determination of which will require further investigation.  These unknown targets are 
represented by question marks within the figure. 
4.2.2 Part II 
A model of the functional roles for Nox2 and Nox4 in c-kit
+
 CPC differentiation and 
alteration of cardiac gene transcript is depicted in Figure 4.2.  Following viral knockdown 
of Nox2 (Figure 4.2A), I noted a significant increase in the expression of precursor cell 
markers c-kit and in Flk-1.  I also noticed a decrease in expression of α-SMA, indicating 
a reduction in the existence of mature smooth muscle cells.  This occurred in a Nox 
isoform specific manner.  In trying to tease apart the mechanisms by which silencing 
Nox2 altered the differentiation status of c-kit
+ 
CPCs, I investigated the expression levels 
of several transcriptions factors and cytokines involved in mesodermal development.  As 
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Figure 4.2.  Functional Roles for Nox2 and Nox4 in C-kit
+
 CPC Differentiation (Part II). 
(A) In AdsiNox2 treated CPCs, there was a significant increase in transcript level for CPC 
markers, c-kit and Flk-1, and cytokine, TGF-β1, along with a decrease in mRNA level for 
transcription factor, Gata6, and mature smooth muscle marker, α-SMA.  (B) In AdsiNox4 
treated CPCs, there was a significant increase in transcript level for Flk-1, transcription factor, 
Gata4, and TGF-β1, along with a decrease in mRNA level for mature cardiac marker, cTnT.  
(C) In AdsiNox2/4 treated CPCs, there was a significant increase in transcript level for c-kit, 
Flk-1, Gata4, and TGF-β1, along with a decrease in mRNA level for Gata 6 and mature 
markers, α-SMA and cTnT.  Legend:  Thin black arrow = direction of differentiation; Dotted 
black arrow = possible contribution to mature cell type; Strike-through = silenced gene; Thick 
upward black arrow = increase in transcript; Thick downward black arrow = decrease in 
transcript; n.c. = no change in transcript.  Abbreviations: E-PC- Endothelial Precursor Cell, 
SM-PC- Smooth Muscle Precursor Cell, CM-PC- Cardiomyocyte Precursor Cell, EC-
Endothelial Cell, SMC- Smooth Muscle Cell, CM- Cardiomyocyte 
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depicted in the model (Figure 4.2A), I saw a significant reduction in Gata6 expression as 
well as a rise in TGF-β1.  This is not surprising given the literature which suggests 
negative regulation of TGF-β1 by Gata6 59 and the necessity of Gata6 for the maintenance 
of a mature phenotype in VSMCs 60.  As such, I believe that an intricate feedback loop, 
shown by the bi-directional black arrow linking TGF-β1 and Gata6, may be at work 
between these two molecules and, ultimately, there is a need for sufficient Gata6 
expression to maintain mature smooth muscle cells.  Interestingly, knockdown of Nox2 
led to a statistically significant decrease in the percent of cells positive for cTnT (not 
depicted), even though the level of cTnT transcript was unchanged from control, 
suggesting critical roles for additional transcription factors, cytokines, and signaling 
pathways that are yet to be uncovered.  In this condition, I saw no change in either 
VEGF-A, a growth factor necessary for endothelial cell differentiation, or vWF 
expression, suggesting little effect on the endothelial cell fate. 
 
After silencing Nox4 (Figure 4.2B), I saw a significant upregulation of Flk-1 expression 
as well as no change in smooth muscle cell commitment, even though an upregulation of 
TGF-β1 was observed.  This further verifies a crucial role for adequate Gata6 levels in 
the progression of c-kit
+
 CPCs to the mature smooth muscle cell phenotype.  This finding 
also leaves open the possibility of alternative regulators of Gata6 that were not examined 
in my studies.  The fact that I did not observe any change in α-SMA at the transcript or 
protein level (not depicted) in this condition suggests that Nox4 does not play an 
important role in smooth muscle cell generation in our system even though it does in 
ESCs 54.  Knockdown of Nox4 did, however, exhibit a cardiac specific phenotype, 
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resulting in increased expression of Gata4 which marks the early cardiac fate and 
decreased expression of the more mature cardiac cell marker cTnT.  As Gata4 is 
regulated through both ROS-dependent and ROS-independent pathways, I hypothesize 
that the increase in Gata4 observed after silencing Nox4 is a result of a ROS-independent 
and antioxidant-sensitive mechanism 61.  This is further supported by the fact that Gata4 
is a retinoic-acid inducible transcription factor in the heart 62.  Additional studies are 
required to elucidate these pathways and determine which is at work in this system.  As 
seen in the AdsiNox2 condition (Figure 4.2A), I saw no changes in expression of VEGF-
A or vWF.   
 
Finally, the concomitant suppression of Nox2 and Nox4 (Figure 4.2C) led to a significant 
increase in both c-kit and Flk-1 expression, suggesting the strongest commitment to the 
precursor cell state.  Interestingly, the rise in Flk-1 was even more robust than the 
increases observed with either virus alone (not depicted), signifying some convergence of 
Nox-mediated signaling.  TGF-β1 also demonstrated a strong upregulation in this 
condition, along with further suppression of smooth muscle cell commitment.  This 
finding is at odds with a recent report that TGF-β1 and notch signaling mediate stem cell 
differentiation into smooth muscle cells 55, and I speculate that the notch pathway might 
be compromised by Nox deficiency.  Additional experiments are required to address this 
hypothesis.  While the expression of Gata4 remained the same as that observed with the 
knockdown of Nox4 alone, I observed an even more substantial downregulation of cTnT 
(not depicted).  I hypothesize that the robust increase in TGF-β1 might be playing a role 
here, as our studies from Chapter 2 revealed that addition of TGF-β1 to the culture 
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medium led to a significant decrease in cardiac commitment.  More experimentation is 
necessary to determine if TGF-β1 is acting agonist or antagonist to cardiac commitment 
in this system, this uncertainty is depicted by the dotted black arrow (Figure 4.2).  The 
considerable increase in TGF-β1 might also reflect an even broader feedback loop in cells 
faced with a drastic loss of Nox signaling, as TGF-β1 is a known activator of Nox 
enzymes.  This feedback looks is shown by an arrow linking TGF-β1 to Nox2 and Nox4 
transcript expression (Figure 4.2).  In the combined viral condition (Figure 4.2C), there 
was no effect on VEGF-A or vWF expression, suggesting a minimal roles for Nox2- and 
Nox4-mediated signaling in endothelial cell commitment.  It remains to be seen how well 
this genetically altered population fairs when transplanted into the infarcted heart.  
Although, I suspect that increased expression of stemness genes and an overall lower 
ROS state will give these cells a survival advantage and allow them to engraft in the 
hostile environment of the ischemic myocardium.   
4.3 Future Directions 
 
While I feel that these studies have provided insight into the molecular foundations of c-kit
+
 CPC 
function, the findings introduce new questions that need to be addressed to fully understand the 
mechanisms controlling c-kit
+
 CPC stemness and differentiation.  Several of these questions are 
discussed in detail below. 
 
1) In addition to changes observed in transcription factor and cytokine expression 
following transduction with AdsiNox2 and AdsiNox4, what signaling pathways are involved 
in Nox2- and Nox4-mediated c-kit
+
 CPC specification?   
 168 
 
Based on studies in ESCs, it is known that Nox-derived ROS act through signaling pathways 
such as Jak/STAT and ERK1/2 as well as redox sensitive transcriptions factors like NF- κβ to 
exert their effects on cardiac differentiation 17, 63, 64.  In addition, there is very clear evidence 
implicating Nox4-derived ROS in p38MAPK activity and the translocation of cardiac 
transcription factor, Mef2c, to the nucleus 51.  Additional studies suggest a critical relationship 
between Nox-derived ROS and eNOS phosphorylation which modulates ESC-mediated 
cardiomyogenesis 50, 65.  Therefore, I propose to carry out a series of Western immunoblots to 
detect phosphorylation of some of these key molecules including p-JAK, p-STAT, p-ERK1/2, p-
p38MAPK, and p-eNOS following treatment of c-kit
+
 CPCS with AdsiNox2, AdsiNox4, 
AdsiNox2/4, or AdsiCON.  As described by Shah, et al. 66, it is well-established that the Nox 
isoforms mediate distinct cell signaling for a variety of reasons including divergent subcellular 
localization.  Therefore, I predict that these studies will elucidate the mechanisms by which 
Nox2- and Nox4-derived ROS facilitate c-kit
+
 CPC differentiation along the smooth muscle and 
cardiac lineages, respectively, as well as shed light upon their convergent signaling pathways.  
Further teasing apart these signaling pathways will also help me understand the alterations that I 
observed in Gata6, Gata4, and TGF-β1 expression following viral knockdown of Nox2 and Nox4 
(Chapter 3: Figure 3.8) and will lead to a more accurate model of c-kit
+
 CPC specification. 
 
2) In addition to an increase in stemness gene expression and a decrease in cardiac cell 
lineage commitment, do c-kit
+
 CPCs transduced with AdsiNox2 and AdsiNox4 also regain a 
protected low ROS profile? 
In order to address this question, first I propose to perform DHE microfluorography as in 
Chapter 3: Figure 3.2, except here I will measure ROS levels 7 days following infection with 
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AdsiNox2, AdsiNox4, AdsiNox2/4, or AdsiCON.  While our laboratory has performed similar 
studies both in cultured cells as well as in vivo 67, 68, I understand the importance of this 
verification in my system.  Following confirmation of a functional decrease in ROS production 
after knockdown of Nox2 and Nox4, next, I will perform RT
2
Profiler PCR Arrays as in Chapter 
3: Figure 3.9 and Tables 3.2 and 3.3 to measure the mRNA expression levels of 84 different 
genes involved in Mouse Oxidative Stress and Antioxidant Defense 7 days following viral 
transduction.  This will allow me to compare the expression levels of each of the redox genes 
following knockdown of Nox2 and Nox4 to those already established for freshly isolated c-kit
+
 
CPCs.  I suspect that the more differentiated AdsiCON cells will show a tip in redox balance to a 
more oxidized state compared to freshly isolated c-kit
+
 CPCs as I already know that Nox2 and 
Nox4 are unregulated by Day 14 of differentiation.  In addition, I expect that each of the Nox 
knockdown conditions will demonstrate a more reduced phenotype, a profile similar to that 
observed in freshly isolated c-kit
+ 
CPCs.  This reversal to a more protected redox state also has 
been observed in iPSCs 69.  I speculate that these studies will provide additional redox targets that 
will be useful in genetic strategies for cardiac repair. 
 
3) What is the regenerative potential of our c-kit
+
 CPC population genetically modified to 
silence expression of Nox2 and Nox4 in vivo?  How can we trace these cells after 
transplantation into the infarcted myocardium? 
Up to this point, I have focused mainly on determining how altered expression of Nox isoforms 
in c-kit
+
 CPCs through viral manipulation can impact their precursor status and differentiation in 
vitro.  Here, I will investigate the regenerative capacity of genetically altered c-kit
+
 CPCs in the 
infarct region as it is well-established that free radicals are a major underlying mechanism of 
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graft cell death 70.  In order to determine the survival rate and proliferative capacity of c-kit
+
 
CPCs genetically engineered for Nox isoforms (Nox2 and Nox4) and a luciferase reporter, I 
propose to use in vivo bioluminescence following transplantation which is a monitoring tool 
widely used in small animal studies.  I anticipate that c-kit
+
 CPCs transduced with AdsiNox2 and 
AdsiNox4 will demonstrate increased survival and proliferation in and around the infarct region 
compared to AdsiCON treated cells as indicated by increased photon emission over longer 
periods of time.   
 
To determine the potential of genetically engineered c-kit
+
 CPCs to differentiate into 
cardiomyocytes in vivo, mice will be sacrificed for immunohistochemistry at several time-points 
post-MI and quantification of differentiation into the three cardiac lineages will be established.  
Because both c-kit
+ 
CPCs isolated from c-kit
BAC
-EGFP mice and the Ad-vectors carry EGFP 
reporters, AdLuciferase immunostaining will be utilized to distinguish between transplanted and 
endogenous cells.  I hypothesize that knockdown of the Noxes will give survival advantage to 
transplanted cells during the first week post-MI, a period known to be hostile to therapeutic 
populations, and, thereafter, either exogenous ROS or Nox-mediated ROS production after 
transient transgene expression diminishes, will allow these cells to differentiate effectively.  
Although I am most interested in an increase in cardiomyocyte generation as indicated by the 
presence of cTnT, I will also analyze cardiac sections for early cardiac marker Gata4 as well as 
markers for smooth muscle cells (Gata6 and α-SMA) and endothelial cells (PECAM1 and vWF) 
to determine the fate of injected c-kit
+
 CPCs. 
 
If I observe significant cardiac regeneration, I am prepared to perform functional studies utilizing 
the Vevo 770 high-resolution imaging system (VisualSonics) in a subset of mice as described by 
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our laboratory 71.  In addition, I am cognizant of the limitations of adenoviral gene transfer to 
mediate long-term transduction of cardiac tissue 72, however our laboratory’s studies suggest that 
gene expression peaks and remains viable through at least Day 14 73. I am prepared in future 
studies to employ other viral vectors such as lentiviruses and adeno-associated viruses to study 
longer time-points if warranted.    The use of lentiviruses for genetic modification of therapeutic 
cell populations provides a unique advantage in that self-renewal, clonogenicity, and 
multipotentiality can be analyzed in vivo by detecting viral integration sites through PCR 74.  
Utilizing a fluorescent reporter, CPCs transduced with virus can be isolated by FACS and 
separated by lineage using commercially available antibodies to identify smooth muscle, cardiac, 
and endothelial cells.  Clones and their progeny then can be identified as those having identical 
molecular weight bands corresponding to the viral site of integration into the host genome.  
While this method would provide critical information regarding the stemness and differentiation 
capacity of genetically altered cells, I am unsure of the biological impact that long-term silencing 
of Nox2 and Nox4 will have on c-kit
+
 CPCs, as it is clear that these two Nox isoforms are critical 
for their final differentiation into smooth and cardiac muscle.   
 
4) What other modifications might improve the survival, engraftment, and regenerative 
ability of our genetically altered c-kit
+
 CPC population? 
It is well-known that extracellular matrices play an essential role in myocardial function and 
provide critical signaling for precursor cell recruitment, activation, and maturation.  Therefore, 
researchers in the field of regenerative cardiology have begun to investigate biomaterials as a 
way to enhance CPC engraftment and function in the damaged myocardium.  In animal models, 
it has been demonstrated that biomaterials such as collagen and fibrin increase retention of 
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exogenously delivered precursor cells in the ischemic region and limit redistribution to other 
organs in the body 75, 76.  In addition, delivery of proteins such as IGF-1, a growth factor known 
to play an important role in cardiomyogenesis, can be achieved through the use of biotinylated 
self-assembling peptides.  When introduced alongside cardiac stem cells, addition of IGF-1 
enhanced myocardial function and increased the generation of mature cardiomyocytes 77.  Tissue 
engineering also can alter the physical microenvironment of therapeutic cell populations by 
accounting for important characteristics such as matrix stiffness, nanotopography, and 
mechanosensory stimuli 78.  Therefore, collaboration with tissue bioengineers is not only advised, 
but likely will prove necessary for cell-based therapy to reach its full potential in clinical trials.  
 
More long-term goals will be to analyze the c-kit
+
 CPC population at the level of the proteome 
and epigenome.  While microarrays and microRNA microarrays are invaluable tools that have 
led to critical discoveries in the field of regenerative cardiology, it is well known that the 
transcriptome is not linearly proportional to the proteome and, often, the quantification of mRNA 
levels is not sufficient to fully understand intricate signaling pathways such as those directing 
CPC differentiation 79.  Utilizing modern tools available in proteomics research, it is possible to 
compare protein profiles of CPCs to those of CPC-derived smooth, cardiac, and endothelial cells 
as well as CPC-derived committed cells to their mature counterparts within the heart.  This type 
of analysis not only will reveal the pathways involved in CPC differentiation, but also the 
validity of utilizing CPC-derived mature cells in cardiac repair 80.  In addition, it is clear that 
epigenetic modifications such as methylation, post-translational histone modification, and 
chromatin remodeling are critically involved in stemness and lineage specification 81, 82.  
Therefore, understanding the epigenetic modifications involved in c-kit
+
 CPC stemness and 
 173 
 
differentiation as well as the stimuli that trigger these events will provide additional avenues for 
enhancing the regenerative capacity of c-kit
+
 CPCs in vivo. 
 
4.4 Concluding Remarks 
 
In this thesis, I have provided clear evidence regarding the stemness of early neonatal c-kit
+ 
CPCs and data to suggest strong redox influence over c-kit
+
 CPC status and differentiation.  I 
have also highlighted several target molecules, transcription factors, and a cytokine that are 
involved in c-kit
+
 CPC stemness and differentiation as well as proposed additional experiments 
to further unravel the molecular complexities of c-kit
+
 CPC function along with strategies to 
enhance their therapeutic potential in vivo.  While my studies provide some of the earliest 
attempts to understand the roles for ROS in CPC biology, I recognize that there is still a lot to 
learn before clinical application is warranted.  As such, the interplay between redox biology and 
c-kit
+
 CPC state is still a very active area of research and discovery, which likely will lead to a 
more precise understanding of the pathways and molecules involved in c-kit
+
 CPC lineage 
commitment.   
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